DiCE Clinical Trials Database

Patients undergoing treatment often ask about the possibility of enrolling in a clinical trial. A clinical trial is a scientific study. It tests new molecules in the hope that they are safe and more effective than current treatments.

This database is based on clinicaltrials.gov – a global clinical trials database of all diseases and all molecules in development worldwide. It is a shortened version of this, focusing on current clinical trials related to digestive cancers in Europe. The information is updated daily.

Important to remember: please always discuss with your treating physicians first your considerations of partaking in a clinical trial. They are the best judges of its benefits to your particular case.

NCT ID Name Study type Phase Status Country Disease type More infos
NCT00002692 Intravenous Compared With Intrahepatic Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver Interventional Phase 3 Unknown status United Kingdom Colorectal Cancer Infos
NCT00002692 Intravenous Compared With Intrahepatic Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver Interventional Phase 3 Unknown status United Kingdom Metastatic Cancer Infos
NCT00002793 Chemotherapy Via an Implantable Pump Compared With a Subcutaneous Port for Unresectable Liver Metastases in Patients With Resected Colorectal Cancer Interventional Phase 3 Unknown status Germany Colorectal Cancer Infos
NCT00002793 Chemotherapy Via an Implantable Pump Compared With a Subcutaneous Port for Unresectable Liver Metastases in Patients With Resected Colorectal Cancer Interventional Phase 3 Unknown status Germany Metastatic Cancer Infos
NCT00002883 Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus Interventional Phase 3 Unknown status France Gastric Cancer Infos
NCT00002893 Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer Interventional Phase 3 Unknown status United Kingdom Colorectal Cancer Infos
NCT00002896 Radiation Therapy Plus Chemotherapy Before Surgery With or Without Chemotherapy After Surgery in Treating Patients With Rectal Cancer Interventional Phase 3 Unknown status Italy Colorectal Cancer Infos
NCT00003063 Biological Therapy With Combination Chemotherapy in Patients With Colorectal Cancer Interventional Phase 3 Unknown status Greece Colorectal Cancer Infos
NCT00003063 Biological Therapy With Combination Chemotherapy in Patients With Colorectal Cancer Interventional Phase 3 Unknown status Italy Colorectal Cancer Infos
NCT00003260 Combination Chemotherapy in Treating Patients With Recurrent Metastatic Colorectal Cancer Interventional Phase 3 Unknown status France Colorectal Cancer Infos
NCT00003617 Chlorambucil Compared With No Further Therapy Following Anti-Helicobacter Therapy in Treating Patients With Low-Grade Lymphoma of the Stomach Interventional Phase 3 Unknown status Poland Gastric Cancer Infos
NCT00003617 Chlorambucil Compared With No Further Therapy Following Anti-Helicobacter Therapy in Treating Patients With Low-Grade Lymphoma of the Stomach Interventional Phase 3 Unknown status Switzerland Gastric Cancer Infos
NCT00003617 Chlorambucil Compared With No Further Therapy Following Anti-Helicobacter Therapy in Treating Patients With Low-Grade Lymphoma of the Stomach Interventional Phase 3 Unknown status United Kingdom Gastric Cancer Infos
NCT00003652 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Interventional Phase 3 Unknown status France Anal Cancer Infos
NCT00004115 Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy Interventional Phase 3 Unknown status United Kingdom Ovarian Cancer Infos
NCT00004115 Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy Interventional Phase 3 Unknown status United Kingdom Primary Peritoneal Cavity Cancer Infos
NCT00004236 Liposomal Doxorubicin in Treating Patients With Advanced Stomach Cancer Interventional Phase 2 Unknown status United Kingdom Gastric Cancer Infos
NCT00005944 Second-look Surgery With or Without Intraperitoneal Chemotherapy in Treating Patients With Recurrent Colorectal Cancer Interventional Phase 2 Unknown status Belgium Colorectal Cancer Infos
NCT00005944 Second-look Surgery With or Without Intraperitoneal Chemotherapy in Treating Patients With Recurrent Colorectal Cancer Interventional Phase 2 Unknown status Belgium Metastatic Cancer Infos
NCT00005944 Second-look Surgery With or Without Intraperitoneal Chemotherapy in Treating Patients With Recurrent Colorectal Cancer Interventional Phase 2 Unknown status Belgium Primary Peritoneal Cavity Cancer Infos
NCT00005944 Second-look Surgery With or Without Intraperitoneal Chemotherapy in Treating Patients With Recurrent Colorectal Cancer Interventional Phase 2 Unknown status France Colorectal Cancer Infos
NCT00005944 Second-look Surgery With or Without Intraperitoneal Chemotherapy in Treating Patients With Recurrent Colorectal Cancer Interventional Phase 2 Unknown status France Metastatic Cancer Infos
NCT00005944 Second-look Surgery With or Without Intraperitoneal Chemotherapy in Treating Patients With Recurrent Colorectal Cancer Interventional Phase 2 Unknown status France Primary Peritoneal Cavity Cancer Infos
NCT00005979 Combination Chemotherapy With or Without Irinotecan in Treating Patients With Stage III Colon Cancer Interventional Phase 3 Unknown status France Colorectal Cancer Infos
NCT00006050 Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver Interventional Phase 2 Unknown status France Colorectal Cancer Infos
NCT00006050 Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver Interventional Phase 2 Unknown status France Metastatic Cancer Infos
NCT00006112 Fluorouracil With or Without Mitomycin in Treating Patients With Peritoneal Cancer Interventional Phase 2 Unknown status France Carcinoma of the Appendix Infos
NCT00006112 Fluorouracil With or Without Mitomycin in Treating Patients With Peritoneal Cancer Interventional Phase 2 Unknown status France Colorectal Cancer Infos
NCT00006112 Fluorouracil With or Without Mitomycin in Treating Patients With Peritoneal Cancer Interventional Phase 2 Unknown status France Primary Peritoneal Cavity Cancer Infos
NCT00006115 Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Interventional Phase 2 Unknown status France Colorectal Cancer Infos
NCT00006117 Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Interventional Phase 2 Unknown status Belgium Pancreatic Cancer Infos
NCT00006117 Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Interventional Phase 2 Unknown status France Pancreatic Cancer Infos
NCT00006468 Comparing Two Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer Interventional Phase 3 Unknown status France Colorectal Cancer Infos
NCT00006479 Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer Interventional Phase 3 Unknown status Austria Colorectal Cancer Infos
NCT00006479 Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer Interventional Phase 3 Unknown status Austria Metastatic Cancer Infos
NCT00006479 Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer Interventional Phase 3 Unknown status Belgium Colorectal Cancer Infos
NCT00006479 Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer Interventional Phase 3 Unknown status Belgium Metastatic Cancer Infos
NCT00006479 Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer Interventional Phase 3 Unknown status France Colorectal Cancer Infos
NCT00006479 Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer Interventional Phase 3 Unknown status France Metastatic Cancer Infos
NCT00006479 Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer Interventional Phase 3 Unknown status Germany Colorectal Cancer Infos
NCT00006479 Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer Interventional Phase 3 Unknown status Germany Metastatic Cancer Infos
NCT00006479 Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer Interventional Phase 3 Unknown status Italy Colorectal Cancer Infos
NCT00006479 Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer Interventional Phase 3 Unknown status Italy Metastatic Cancer Infos
NCT00006479 Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer Interventional Phase 3 Unknown status Netherlands Colorectal Cancer Infos
NCT00006479 Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer Interventional Phase 3 Unknown status Netherlands Metastatic Cancer Infos
NCT00006479 Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer Interventional Phase 3 Unknown status Norway Colorectal Cancer Infos
NCT00006479 Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer Interventional Phase 3 Unknown status Norway Metastatic Cancer Infos
NCT00006479 Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer Interventional Phase 3 Unknown status Portugal Colorectal Cancer Infos
NCT00006479 Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer Interventional Phase 3 Unknown status Portugal Metastatic Cancer Infos
NCT00006479 Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer Interventional Phase 3 Unknown status Sweden Colorectal Cancer Infos
NCT00006479 Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer Interventional Phase 3 Unknown status Sweden Metastatic Cancer Infos
NCT00006479 Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer Interventional Phase 3 Unknown status United Kingdom Colorectal Cancer Infos
NCT00006479 Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer Interventional Phase 3 Unknown status United Kingdom Metastatic Cancer Infos
NCT00007826 Monoclonal Antibody Therapy and/or Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer Interventional Phase 1/Phase 2 Unknown status United Kingdom Colorectal Cancer Infos
NCT00010062 Fluorouracil Plus Radiation Therapy Following Surgery in Treating Patients With Pancreatic Cancer Interventional Phase 2 Unknown status France Pancreatic Cancer Infos
NCT00010062 Fluorouracil Plus Radiation Therapy Following Surgery in Treating Patients With Pancreatic Cancer Interventional Phase 2 Unknown status Luxembourg Pancreatic Cancer Infos
NCT00010088 Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas or Bile Duct Interventional Phase 2 Unknown status France Pancreatic Cancer Infos
NCT00010088 Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas or Bile Duct Interventional Phase 2 Unknown status Luxembourg Pancreatic Cancer Infos
NCT00010270 LMB-9 Immunotoxin in Treating Patients With Advanced Pancreatic, Esophageal, Stomach, Colon, or Rectal Cancer Interventional Phase 1 Unknown status Germany Colorectal Cancer Infos
NCT00010270 LMB-9 Immunotoxin in Treating Patients With Advanced Pancreatic, Esophageal, Stomach, Colon, or Rectal Cancer Interventional Phase 1 Unknown status Germany Gastric Cancer Infos
NCT00010270 LMB-9 Immunotoxin in Treating Patients With Advanced Pancreatic, Esophageal, Stomach, Colon, or Rectal Cancer Interventional Phase 1 Unknown status Germany Pancreatic Cancer Infos
NCT00024375 DHA-Paclitaxel in Treating Patients With Metastatic Pancreatic Cancer Interventional Phase 2 Unknown status Germany Pancreatic Cancer Infos
NCT00024375 DHA-Paclitaxel in Treating Patients With Metastatic Pancreatic Cancer Interventional Phase 2 Unknown status Netherlands Pancreatic Cancer Infos
NCT00024375 DHA-Paclitaxel in Treating Patients With Metastatic Pancreatic Cancer Interventional Phase 2 Unknown status United Kingdom Pancreatic Cancer Infos
NCT00033319 Aspirin and/or Folic Acid in Preventing Recurrent Colorectal Polyps Interventional N/A Unknown status United Kingdom Colorectal Cancer Infos
NCT00045461 Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Interventional Phase 2/Phase 3 Unknown status Germany Fallopian Tube Cancer Infos
NCT00045461 Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Interventional Phase 2/Phase 3 Unknown status Germany Ovarian Cancer Infos
NCT00045461 Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Interventional Phase 2/Phase 3 Unknown status Germany Primary Peritoneal Cavity Cancer Infos
NCT00045461 Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Interventional Phase 2/Phase 3 Unknown status Hungary Fallopian Tube Cancer Infos
NCT00045461 Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Interventional Phase 2/Phase 3 Unknown status Hungary Ovarian Cancer Infos
NCT00045461 Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Interventional Phase 2/Phase 3 Unknown status Hungary Primary Peritoneal Cavity Cancer Infos
NCT00045461 Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Interventional Phase 2/Phase 3 Unknown status Netherlands Fallopian Tube Cancer Infos
NCT00045461 Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Interventional Phase 2/Phase 3 Unknown status Netherlands Ovarian Cancer Infos
NCT00045461 Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Interventional Phase 2/Phase 3 Unknown status Netherlands Primary Peritoneal Cavity Cancer Infos
NCT00046995 Combination Chemotherapy in Treating Patients With Colon Cancer Interventional Phase 3 Unknown status Belgium Colorectal Cancer Infos
NCT00066274 Comparison of Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer Interventional Phase 2 Unknown status France Colorectal Cancer Infos
NCT00070005 J-Pouch Coloanal Anastomosis Compared With Side-to-End Coloanal Anastomosis After Radiation Therapy and Surgery to Remove the Rectum in Treating Patients With Rectal Adenocarcinoma Interventional Phase 3 Unknown status Netherlands Colorectal Cancer Infos
NCT00070213 Leucovorin and Fluorouracil With or Without Oxaliplatin Compared to Capecitabine With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer Interventional Phase 3 Unknown status United Kingdom Colorectal Cancer Infos
NCT00072553 Celecoxib, Leucovorin, Fluorouracil, and Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer Interventional Phase 2 Unknown status France Colorectal Cancer Infos
NCT00075452 Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Unresectable Pancreatic Adenocarcinoma Interventional Phase 3 Unknown status France Pancreatic Cancer Infos
NCT00075465 Docetaxel and Epirubicin as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Adenocarcinoma of the Stomach Interventional Phase 2 Unknown status France Gastric Cancer Infos
NCT00075556 Neoadjuvant Radiation Therapy and Capecitabine in Treating Patients With Stage III or Stage IV Colorectal Adenocarcinoma Interventional Phase 2 Unknown status France Colorectal Cancer Infos
NCT00075595 Fluorouracil, Leucovorin, and Irinotecan in Treating Patients With Recurrent or Refractory Metastatic Unresectable Colorectal Cancer Interventional Phase 2 Unknown status France Colorectal Cancer Infos
NCT00077389 Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk Hepatoblastoma Interventional Phase 2 Unknown status France Liver Cancer Infos
NCT00077389 Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk Hepatoblastoma Interventional Phase 2 Unknown status Ireland Liver Cancer Infos
NCT00077389 Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk Hepatoblastoma Interventional Phase 2 Unknown status Netherlands Liver Cancer Infos
NCT00077389 Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk Hepatoblastoma Interventional Phase 2 Unknown status United Kingdom Liver Cancer Infos
NCT00079027 Doxorubicin By Infusion or Chemoembolization in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer) Interventional Phase 3 Unknown status United Kingdom Liver Cancer Infos
NCT00091312 Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer Interventional Phase 3 Unknown status France Colorectal Cancer Infos
NCT00091312 Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer Interventional Phase 3 Unknown status Germany Colorectal Cancer Infos
NCT00091312 Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer Interventional Phase 3 Unknown status Italy Colorectal Cancer Infos
NCT00091312 Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer Interventional Phase 3 Unknown status Portugal Colorectal Cancer Infos
NCT00091312 Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer Interventional Phase 3 Unknown status Spain Colorectal Cancer Infos
NCT00104689 Capecitabine and Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer Interventional Phase 2 Unknown status France Colorectal Cancer Infos
NCT00108875 Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer Interventional Phase 1/Phase 2 Unknown status Germany Colon Cancer Infos
NCT00108875 Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer Interventional Phase 1/Phase 2 Unknown status Germany Pancreatic Cancer Infos
NCT00112658 Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer Interventional Phase 2/Phase 3 Unknown status France Pancreatic Cancer Infos
NCT00112697 Radiation Therapy and Docetaxel With Either Fluorouracil or Cisplatin as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery Interventional Phase 2 Unknown status France Pancreatic Cancer Infos
NCT00114829 Preoperative Assessment of Colon Tumor Interventional Phase 4 Unknown status Denmark Colorectal Cancer Infos
NCT00119912 NORCCAP: Norwegian Colorectal Cancer Prevention Trial Interventional N/A Active but recruitment closed Norway Adenoma Infos
NCT00119912 NORCCAP: Norwegian Colorectal Cancer Prevention Trial Interventional N/A Active but recruitment closed Norway Colorectal Cancer Infos
NCT00121914 Treatment of Hepatocellular Carcinoma: Long-Acting Somatostatin Plus Percutaneous Ethanol Instillation (PEI) Versus Long-Acting Somatostatin Alone Interventional Phase 3 Unknown status Austria Carcinoma, Hepatocellular Infos
NCT00134758 Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) Patients Interventional Phase 2/Phase 3 Unknown status France Adenomatous Polyposis Coli, Familial Infos
NCT00141466 Implementation of a New Strategy to Identify HNPCC Patients Interventional N/A Unknown status Netherlands Hereditary Nonpolyposis Colorectal Cancer Infos
NCT00162669 Bevacizumab in Advanced Hepatocellular Carcinoma Interventional Phase 2 Unknown status France Hepatocellular Carcinoma Infos
NCT00182715 Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer Interventional Phase 3 Unknown status Ireland Colorectal Cancer Infos
NCT00182715 Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer Interventional Phase 3 Unknown status United Kingdom Colorectal Cancer Infos
NCT00188110 Performance of the Water-Enema Computed Tomography (WE-CT) Interventional N/A Unknown status France Colon Cancer Infos
NCT00189683 Xeloda Vs Monitoring in Advanced Colorectal Cancer Responsive to Chemotherapy Interventional Phase 3 Unknown status France Colorectal Cancer Infos
NCT00197873 Lactobacillus Rhamnosus in Prevention of Chemotherapy-related Diarrhoea Interventional N/A Unknown status Finland Colorectal Cancer Infos
NCT00212615 XELOX III. Xeloda in Combination With Eloxatin for Patients With Advanced or Metastatic Colorectal Cancer Interventional Phase 2/Phase 3 Unknown status Denmark C04.588.274.476.411.307 Infos
NCT00212615 XELOX III. Xeloda in Combination With Eloxatin for Patients With Advanced or Metastatic Colorectal Cancer Interventional Phase 2/Phase 3 Unknown status Sweden C04.588.274.476.411.307 Infos
NCT00215722 XELOX Plus Cetuximab as First-Line Therapy in Patients With Metastatic Colorectal Cancer Interventional Phase 2 Unknown status Portugal Colorectal Carcinoma Infos
NCT00220077 Determination of the Role of Microarray for Prognosis and Prediction to Chemotherapy Sensitivity in Patients With Operable, Locally Advanced and Metastatic Oesophageal Cancer Interventional N/A Unknown status United Kingdom Oesophageal Cancer Infos
NCT00220246 Clinical and Molecular Characterization of Familial Microsatellite Stable Colorectal Cancer Observational N/A Unknown status Netherlands Colorectal Neoplasms Infos
NCT00225641 Assessment of Frequency of Surveillance After Curative Resection in Patients With Stage II and III Colorectal Cancer Interventional N/A Unknown status Denmark Colorectal Cancer Infos
NCT00227747 Radiation Therapy and Capecitabine With or Without Oxaliplatin in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Rectal Cancer Interventional Phase 3 Unknown status France Colorectal Cancer Infos
NCT00250328 Evaluation of NiTi Laparoscopic Compression Anastomosis Clip (LapCAC) Device for Intra-Corporeal Lap-Colectomy Interventional Phase 1 Unknown status Israel Colon Cancer Infos
NCT00253812 Adenoma Detection Rate:NBI, AFI, Chromoscopic or Standard Endoscopy Interventional N/A Unknown status United Kingdom Familial Adenomatous Polyposis Infos
NCT00259532 Three New Methods for Diagnosing Pancreas Cancer Interventional N/A Unknown status Denmark Pancreas Cancer Infos
NCT00268411 Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer Interventional Phase 3 Unknown status France Pancreatic Cancer Infos
NCT00274872 Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery Interventional Phase 2/Phase 3 Unknown status France Colorectal Cancer Infos
NCT00274885 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Interventional Phase 4 Unknown status France Cancer Infos
NCT00275119 Gemcitabine and Oxaliplatin Followed By Radiation Therapy, Fluorouracil, and Oxaliplatin in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery Interventional Phase 2 Unknown status France Pancreatic Cancer Infos
NCT00276705 Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer Interventional Phase 2 Unknown status Ireland Liver Cancer Infos
NCT00276705 Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer Interventional Phase 2 Unknown status United Kingdom Liver Cancer Infos
NCT00287976 Irinotecan in Treating Young Patients With Refractory or Recurrent Hepatoblastoma Interventional Phase 2 Unknown status Ireland Liver Cancer Infos
NCT00287976 Irinotecan in Treating Young Patients With Refractory or Recurrent Hepatoblastoma Interventional Phase 2 Unknown status Netherlands Liver Cancer Infos
NCT00287976 Irinotecan in Treating Young Patients With Refractory or Recurrent Hepatoblastoma Interventional Phase 2 Unknown status United Kingdom Liver Cancer Infos
NCT00299299 Modelling Internal Hepatic Movement With an External Abdominal Marker Observational N/A Unknown status United Kingdom Patients With Liver Metastases From Colorectal Cancer Infos
NCT00303745 Irinotecan With or Without Capecitabine as Second-Line Therapy in Treating Older Patients With Progressive, Metastatic Colorectal Cancer That Cannot Be Removed By Surgery Interventional Phase 2 Unknown status France Colorectal Cancer Infos
NCT00305838 CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen Interventional Phase 2 Unknown status United Kingdom Fallopian Tube Cancer Infos
NCT00305838 CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen Interventional Phase 2 Unknown status United Kingdom Ovarian Cancer Infos
NCT00305838 CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen Interventional Phase 2 Unknown status United Kingdom Primary Peritoneal Cavity Cancer Infos
NCT00319007 Influence of Sulindac and Probiotics on the Development of Pouch Adenomas in Patients With Familial Adenomatous Polyposis Interventional Phase 2 Unknown status Netherlands Adenomatous Polyposis Coli Infos
NCT00346281 32P BioSiliconTM in Addition to Gemcitabine in Pancreatic Cancer Interventional Phase 2 Unknown status United Kingdom Pancreatic Cancer Infos
NCT00356161 HAI Via Interventionally Implanted Port Catheter Systems Interventional Phase 2 Unknown status Germany Colorectal Cancer Infos
NCT00356161 HAI Via Interventionally Implanted Port Catheter Systems Interventional Phase 2 Unknown status Germany Hepatocellular Carcinoma Infos
NCT00374660 Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors Interventional Phase 1/Phase 2 Unknown status France Liver Cancer Infos
NCT00383695 Oxaliplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients Undergoing Surgery for High-Risk Rectal Cancer Interventional Phase 2 Unknown status Spain Colorectal Cancer Infos
NCT00383695 Oxaliplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients Undergoing Surgery for High-Risk Rectal Cancer Interventional Phase 2 Unknown status Sweden Colorectal Cancer Infos
NCT00383695 Oxaliplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients Undergoing Surgery for High-Risk Rectal Cancer Interventional Phase 2 Unknown status United Kingdom Colorectal Cancer Infos
NCT00389870 Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil Interventional Phase 3 Unknown status United Kingdom Colorectal Cancer Infos
NCT00392470 Radiation Therapy, Irinotecan, and Cetuximab in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Rectal Cancer Interventional Phase 1 Unknown status Switzerland Colorectal Cancer Infos
NCT00407186 Randomized Phase III Trial of Adjuvant Chemotherapy or Chemoradiotherapy in Resectable Gastric Cancer (CRITICS) Interventional Phase 3 Active but recruitment closed Netherlands Gastric Cancer Infos
NCT00411112 Sentinel Node in Colon Cancer Interventional N/A Unknown status France Colon Cancer Infos
NCT00420394 Perioperative Chemoradiotherapy for Potentially Resectable Gastric Cancer Interventional Phase 2 Unknown status Israel Stomach Neoplasms Infos
NCT00423696 Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery Interventional Phase 2 Unknown status France Colorectal Cancer Infos
NCT00433927 5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC) Interventional Phase 3 Unknown status Germany Colorectal Cancer Infos
NCT00433927 5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC) Interventional Phase 3 Unknown status Germany Neoplasm Metastasis Infos
NCT00435097 Computer Assisted Early Detection of Liver Metastases From fMRI Maps Observational N/A Unknown status Israel Metastatic Colorectal Cancer Infos
NCT00438737 Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer Interventional Phase 2 Unknown status France Colorectal Cancer Infos
NCT00438737 Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer Interventional Phase 2 Unknown status France Metastatic Cancer Infos
NCT00440167 Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine Interventional Phase 3 Unknown status Germany Pancreatic Cancer Infos
NCT00442637 Maintenance Treatment Versus Observation After Induction in Advanced Colorectal Carcinoma Interventional Phase 3 Unknown status Netherlands Colorectal Cancer Metastatic Infos
NCT00450203 Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer Interventional Phase 2/Phase 3 Unknown status United Kingdom Oesophagogastric Cancer Infos
NCT00468416 Evaluation of NiTi Shape Memory End-to-End Compression Anastomosis Ring (CAR) for Compression Anastomosis in Anterior Resection Interventional Phase 2 Unknown status Israel Colorectal Cancer Infos
NCT00474734 Intravascular Ultrasound for Hepatocellular Carcinoma Staging Observational N/A Unknown status Switzerland Hepatocellular Carcinoma Infos
NCT00478946 A Study of Picoplatin in Colorectal Cancer Interventional Phase 1/Phase 2 Unknown status Russian Federation Colorectal Cancer Infos
NCT00482222 Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer Interventional Phase 3 Unknown status United Kingdom Colorectal Cancer Infos
NCT00482222 Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer Interventional Phase 3 Unknown status United Kingdom Metastatic Cancer Infos
NCT00486460 Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Advance or Inoperable Pancreatic Cancer Interventional Phase 3 Unknown status Israel Pancreatic Cancer Infos
NCT00501176 Preoperative Stent Study Interventional N/A Unknown status Sweden Pancreas Cancer Infos
NCT00513266 Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery Interventional Phase 2 Unknown status Switzerland Colorectal Cancer Infos
NCT00513266 Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery Interventional Phase 2 Unknown status Switzerland Metastatic Cancer Infos
NCT00514930 Multicentre Prospective Clinical Trial for RFA Tumour Aspirator Treatment of Primary and Secondary Malignancies of the Liver Interventional Phase 1/Phase 2 Unknown status Greece Liver Cancer Infos
NCT00541021 Gemcitabine With or Without Sorafenib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Interventional Phase 3 Unknown status France Pancreatic Cancer Infos
NCT00544011 Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Interventional Phase 2 Unknown status France Colorectal Cancer Infos
NCT00551057 Expression of Inflammatory Proteins in Pancreatic Cancer Observational N/A Unknown status Switzerland Pancreatic Neoplasms Infos
NCT00559858 Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer Interventional Phase 3 Unknown status United Kingdom Breast Cancer Infos
NCT00559858 Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer Interventional Phase 3 Unknown status United Kingdom Colorectal Cancer Infos
NCT00559858 Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer Interventional Phase 3 Unknown status United Kingdom Palmar-plantar Erythrodysesthesia Infos
NCT00560365 Follow-Up Study of Patients Who Have Undergone Surgery for Stage I, Stage II, or Stage III Colorectal Cancer Observational N/A Unknown status United Kingdom Colorectal Cancer Infos
NCT00582257 Early Onset and Familial Gastric Cancer Registry Observational N/A Active but recruitment closed Israel Gastric Cancer Infos
NCT00628368 Biological Factors in Predicting Response to Treatment in Patients With Esophageal Cancer or Rectal Cancer Interventional N/A Unknown status France Colorectal Cancer Infos
NCT00647530 Fluorouracil and Oxaliplatin With or Without Panitumumab In Treating Patients With High-Risk Colon Cancer That Can Be Removed by Surgery Interventional Phase 2/Phase 3 Active but recruitment closed United Kingdom Colorectal Cancer Infos
NCT00669370 Biweekly Docetaxel in Combination With Capecitabine as First-Line Treatment in Patients With Advanced Gastric Cancer Interventional Phase 2 Unknown status Finland Stomach Neoplasms Infos
NCT00680901 LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib Interventional Phase 3 Active but recruitment closed Estonia Neoplasms, Gastrointestinal Tract Infos
NCT00680901 LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib Interventional Phase 3 Active but recruitment closed Hungary Neoplasms, Gastrointestinal Tract Infos
NCT00680901 LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib Interventional Phase 3 Active but recruitment closed Israel Neoplasms, Gastrointestinal Tract Infos
NCT00680901 LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib Interventional Phase 3 Active but recruitment closed Italy Neoplasms, Gastrointestinal Tract Infos
NCT00680901 LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib Interventional Phase 3 Active but recruitment closed Netherlands Neoplasms, Gastrointestinal Tract Infos
NCT00680901 LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib Interventional Phase 3 Active but recruitment closed Poland Neoplasms, Gastrointestinal Tract Infos
NCT00680901 LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib Interventional Phase 3 Active but recruitment closed Russian Federation Neoplasms, Gastrointestinal Tract Infos
NCT00680901 LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib Interventional Phase 3 Active but recruitment closed Turkey Neoplasms, Gastrointestinal Tract Infos
NCT00680901 LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib Interventional Phase 3 Active but recruitment closed Ukraine Neoplasms, Gastrointestinal Tract Infos
NCT00690300 Docetaxel Plus Oxaliplatin as Therapy in Patients With Pancreatic Cancer Interventional Phase 2 Unknown status Germany Pancreas Neoplasms Infos
NCT00693290 Improving Outcomes for Patients Requiring Oral Bowel Preparation for Colonoscopy Interventional N/A Unknown status United Kingdom Colorectal Cancer Infos
NCT00710632 Screening to Predict Weight Loss in Patients With Cancer Interventional N/A Unknown status United Kingdom Gastrointestinal Cancer Infos
NCT00722228 Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors Interventional Phase 1/Phase 2 Recruitment open Israel Colorectal Cancer Infos
NCT00722228 Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors Interventional Phase 1/Phase 2 Recruitment open Israel Gastric Cancer Infos
NCT00756509 Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib Interventional Phase 4 Active but recruitment closed Finland Gastrointestinal Stromal Tumors Infos
NCT00756509 Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib Interventional Phase 4 Active but recruitment closed France Gastrointestinal Stromal Tumors Infos
NCT00756509 Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib Interventional Phase 4 Active but recruitment closed Germany Gastrointestinal Stromal Tumors Infos
NCT00756509 Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib Interventional Phase 4 Active but recruitment closed Italy Gastrointestinal Stromal Tumors Infos
NCT00756509 Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib Interventional Phase 4 Active but recruitment closed Spain Gastrointestinal Stromal Tumors Infos
NCT00757614 Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom Observational N/A Unknown status United Kingdom Pancreatic Cancer Infos
NCT00757640 Gastrectomy Plus Prophylactic Cholecystectomy in Gastric Cancer Surgery Interventional Phase 4 Unknown status Italy Gastric Cancer Infos
NCT00757965 Study of Genes and the Environment in Patients With Colorectal Cancer in the East Anglia Region of the United Kingdom Observational N/A Unknown status United Kingdom Colorectal Cancer Infos
NCT00758381 Metastatic Advanced Pancreas Sorafenib Interventional Phase 2 Unknown status Italy Locally Advanced Pancreatic Cancer Infos
NCT00766142 Combination Chemotherapy and Cetuximab in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer Interventional Phase 2 Unknown status France Colorectal Cancer Infos
NCT00766142 Combination Chemotherapy and Cetuximab in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer Interventional Phase 2 Unknown status France Peritoneal Cavity Cancer Infos
NCT00777478 Capiri-sutent Phase-1 in Advanced Colo-rectal Cancer Interventional Phase 1 Unknown status Netherlands Colorectal Cancer Infos
NCT00777504 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Interventional Phase 4 Unknown status Netherlands Gastrointestinal Stromal Tumor Infos
NCT00790140 Trial of Enteral Nutrition Enriched With Eicosapentaenoic Acid (EPA) in Upper Gastrointestinal Cancer Surgery Interventional Phase 4 Unknown status Ireland Esophageal Cancer Infos
NCT00797251 Anatomical Right Posterior Sectionectomy of the Liver by IOUS-Guided Finger Compression Observational N/A Unknown status Italy Hepatocellular Carcinoma Infos
NCT00797485 Bevacizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Metastatic Colorectal Cancer That Cannot Be Removed By Surgery Interventional Phase 3 Unknown status Italy Colorectal Cancer Infos
NCT00813696 Gemcitabine or Gemcitabine and Cisplatin in the Treatment of Advanced Pancreatic Cancer Interventional Phase 3 Unknown status Italy Pancreatic Cancer Infos
NCT00819208 Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer Interventional N/A Recruitment open France Anxiety Disorder Infos
NCT00819208 Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer Interventional N/A Recruitment open France Cognitive/Functional Effects Infos
NCT00819208 Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer Interventional N/A Recruitment open France Colorectal Cancer Infos
NCT00819208 Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer Interventional N/A Recruitment open France Depression Infos
NCT00819208 Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer Interventional N/A Recruitment open France Excercise Infos
NCT00819208 Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer Interventional N/A Recruitment open France Fatigue Infos
NCT00819208 Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer Interventional N/A Recruitment open France Psychosocial Effects of Cancer and Its Treatment Infos
NCT00819208 Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer Interventional N/A Recruitment open France Sleep Disorders Infos
NCT00819208 Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer Interventional N/A Recruitment open United Kingdom Anxiety Disorder Infos
NCT00819208 Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer Interventional N/A Recruitment open United Kingdom Cognitive/Functional Effects Infos
NCT00819208 Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer Interventional N/A Recruitment open United Kingdom Colorectal Cancer Infos
NCT00819208 Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer Interventional N/A Recruitment open United Kingdom Depression Infos
NCT00819208 Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer Interventional N/A Recruitment open United Kingdom Excercise Infos
NCT00819208 Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer Interventional N/A Recruitment open United Kingdom Fatigue Infos
NCT00819208 Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer Interventional N/A Recruitment open United Kingdom Psychosocial Effects of Cancer and Its Treatment Infos
NCT00819208 Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer Interventional N/A Recruitment open United Kingdom Sleep Disorders Infos
NCT00823290 Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC) Interventional Phase 1 Unknown status Germany Hepatocellular Carcinoma Infos
NCT00825110 SS-GCC1- Screening Study of Genetic Changes in Colorectal Cancer Observational N/A Recruitment open United Kingdom Colorectal Cancer Infos
NCT00838656 Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Interventional Phase 2 Unknown status United Kingdom Fallopian Tube Cancer Infos
NCT00838656 Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Interventional Phase 2 Unknown status United Kingdom Ovarian Cancer Infos
NCT00838656 Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Interventional Phase 2 Unknown status United Kingdom Primary Peritoneal Cavity Cancer Infos
NCT00845884 Phase I/II Study of Weekly Docetaxel and Cisplatin Together With Capecitabine and Bevacizumab in Advanced Gastric Cancer Interventional Phase 1/Phase 2 Unknown status Israel Advanced Gastric Cancer Infos
NCT00848952 Performance of Imaging for the Diagnosis of Small Hepatocellular Carcinoma (< 3 cm)on Cirrhosis Interventional N/A Unknown status France Hepatocellular Carcinoma Infos
NCT00852228 Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy Interventional Phase 2 Unknown status Belgium Hepatic Lesions Infos
NCT00852228 Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy Interventional Phase 2 Unknown status Belgium Liver Metastases Infos
NCT00852228 Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy Interventional Phase 2 Unknown status Belgium Metastatic Colorectal Cancer Infos
NCT00852228 Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy Interventional Phase 2 Unknown status France Hepatic Lesions Infos
NCT00852228 Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy Interventional Phase 2 Unknown status France Liver Metastases Infos
NCT00852228 Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy Interventional Phase 2 Unknown status France Metastatic Colorectal Cancer Infos
NCT00852228 Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy Interventional Phase 2 Unknown status Italy Hepatic Lesions Infos
NCT00852228 Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy Interventional Phase 2 Unknown status Italy Liver Metastases Infos
NCT00852228 Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy Interventional Phase 2 Unknown status Italy Metastatic Colorectal Cancer Infos
NCT00852228 Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy Interventional Phase 2 Unknown status Portugal Hepatic Lesions Infos
NCT00852228 Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy Interventional Phase 2 Unknown status Portugal Liver Metastases Infos
NCT00852228 Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy Interventional Phase 2 Unknown status Portugal Metastatic Colorectal Cancer Infos
NCT00860691 Double Blinded Randomized Clinical Trial of the Effect of Open Versus Laparoscopic Colectomy on Neutrophils in Patients With Colon Cancer Interventional N/A Unknown status Croatia Colonic Neoplasms Infos
NCT00865982 Study to Evaluate Safety and Efficacy of Perioperative Chemotherapy With Docetaxel, Cisplatin and Capecitabine (DCX) in Patients With Gastro-esophageal Cancer Interventional Phase 2 Unknown status Germany Gastric Cancer Infos
NCT00883792 The Northern-European Initiative on Colorectal Cancer Interventional Phase 3 Active but recruitment closed Iceland Colorectal Cancer Infos
NCT00883792 The Northern-European Initiative on Colorectal Cancer Interventional Phase 3 Active but recruitment closed Latvia Colorectal Cancer Infos
NCT00883792 The Northern-European Initiative on Colorectal Cancer Interventional Phase 3 Active but recruitment closed Netherlands Colorectal Cancer Infos
NCT00883792 The Northern-European Initiative on Colorectal Cancer Interventional Phase 3 Active but recruitment closed Norway Colorectal Cancer Infos
NCT00883792 The Northern-European Initiative on Colorectal Cancer Interventional Phase 3 Active but recruitment closed Poland Colorectal Cancer Infos
NCT00883792 The Northern-European Initiative on Colorectal Cancer Interventional Phase 3 Active but recruitment closed Sweden Colorectal Cancer Infos
NCT00884767 Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin Interventional Phase 2 Unknown status France Chemotherapeutic Agent Toxicity Infos
NCT00884767 Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin Interventional Phase 2 Unknown status France Colorectal Cancer Infos
NCT00884767 Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin Interventional Phase 2 Unknown status France Neurotoxicity Infos
NCT00888797 β-adrenergic Blocker and a COX2 Inhibitor for Prevention of Colorectal Cancer Recurrence Interventional Phase 3 Unknown status Israel Colorectal Neoplasms Infos
NCT00903565 A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint Observational N/A Active but recruitment closed Austria Colon Cancer Infos
NCT00903565 A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint Observational N/A Active but recruitment closed Denmark Colon Cancer Infos
NCT00903565 A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint Observational N/A Active but recruitment closed France Colon Cancer Infos
NCT00903565 A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint Observational N/A Active but recruitment closed Germany Colon Cancer Infos
NCT00903565 A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint Observational N/A Active but recruitment closed Netherlands Colon Cancer Infos
NCT00903565 A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint Observational N/A Active but recruitment closed Spain Colon Cancer Infos
NCT00903565 A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint Observational N/A Active but recruitment closed Sweden Colon Cancer Infos
NCT00903565 A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint Observational N/A Active but recruitment closed Switzerland Colon Cancer Infos
NCT00903565 A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint Observational N/A Active but recruitment closed United Kingdom Colon Cancer Infos
NCT00906997 Colorectal Cancer Screening in Average-risk Population: Immunochemical Fecal Occult Blood Testing Versus Colonoscopy Interventional Phase 3 Active but recruitment closed Spain Colorectal Cancer Infos
NCT00906997 Colorectal Cancer Screening in Average-risk Population: Immunochemical Fecal Occult Blood Testing Versus Colonoscopy Interventional Phase 3 Active but recruitment closed Spain Colorectal Neoplasm Infos
NCT00910819 Tumour Registry Colorectal Cancer Observational N/A Active but recruitment closed Germany Colorectal Cancer Infos
NCT00931840 A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma Interventional Phase 2 Unknown status Israel Metastatic Colorectal Cancer Infos
NCT00931840 A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma Interventional Phase 2 Unknown status Netherlands Metastatic Colorectal Cancer Infos
NCT00931840 A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma Interventional Phase 2 Unknown status United Kingdom Metastatic Colorectal Cancer Infos
NCT00934505 Predictive Value of Pet Scan With Fdg Performed During Irradiation in Patients Treated for Oesaphagus Carcinoma Observational N/A Unknown status France Oesophageal Cancer Infos
NCT00947102 Influence of Gemcitabine Treatment on Immunological and Serological Profile in Patients With Pancreatic Cancer Observational N/A Unknown status Slovenia Pancreatic Tubular Adenocarcinoma Infos
NCT00958737 Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon Cancer Interventional Phase 3 Unknown status France Colorectal Cancer Infos
NCT00963092 Study of Blood and Tissue Samples From Patients With Stomach Cancer, Esophageal Cancer, or Gastroesophageal Junction Cancer Observational N/A Unknown status United Kingdom Gastric Cancer Infos
NCT00963352 Colon Cancer Prognosis After Radical Surgery Observational N/A Unknown status Norway Colon Cancer Infos
NCT00964171 Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer Interventional Phase 2 Unknown status France Pancreatic Cancer Infos
NCT00964457 Treatment of Patients With Advanced Rectum Cancer With Capecitabine and Oxaliplatin Before, Under and After Radiation and With Adding Cetuximab to K-RAS Wild-type Patients Interventional Phase 2 Unknown status Denmark Rectum Cancer Infos
NCT00973869 Curcumin in Preventing Colorectal Cancer in Patients Undergoing Colorectal Endoscopy or Colorectal Surgery Interventional Phase 1 Unknown status United Kingdom Colorectal Cancer Infos
NCT00984048 Study to Identify Mechanisms of Resistance to Standard Therapy in Patients With Metastatic Colorectal Cancer Observational N/A Unknown status Belgium Colorectal Cancer Infos
NCT00994864 Preoperative Chemosensitivity Testing to Predict Treatment Benefit in Adjuvant Stage III Colon Cancer Interventional N/A Active but recruitment closed Belgium Colon Cancer Infos
NCT00995202 Follow-Up Care With or Without CEA Assessments in Patients Who Have Undergone Surgery for Stage II or Stage III Colorectal Cancer Interventional Phase 3 Active but recruitment closed Belgium Colorectal Cancer Infos
NCT00995202 Follow-Up Care With or Without CEA Assessments in Patients Who Have Undergone Surgery for Stage II or Stage III Colorectal Cancer Interventional Phase 3 Active but recruitment closed France Colorectal Cancer Infos
NCT01013649 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Interventional Phase 3 Active but recruitment closed Belgium Pancreatic Acinar Cell Carcinoma Infos
NCT01013649 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Interventional Phase 3 Active but recruitment closed Belgium Pancreatic Ductal Adenocarcinoma Infos
NCT01013649 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Interventional Phase 3 Active but recruitment closed Belgium Pancreatic Intraductal Papillary-Mucinous Neoplasm Infos
NCT01013649 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Interventional Phase 3 Active but recruitment closed Belgium Stage IA Pancreatic Cancer AJCC v6 and v7 Infos
NCT01013649 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Interventional Phase 3 Active but recruitment closed Belgium Stage IB Pancreatic Cancer AJCC v6 and v7 Infos
NCT01013649 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Interventional Phase 3 Active but recruitment closed Belgium Stage IIA Pancreatic Cancer AJCC v6 and v7 Infos
NCT01013649 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Interventional Phase 3 Active but recruitment closed Belgium Stage IIB Pancreatic Cancer AJCC v6 and v7 Infos
NCT01013649 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Interventional Phase 3 Active but recruitment closed Belgium Stage II Pancreatic Cancer AJCC v6 and v7 Infos
NCT01013649 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Interventional Phase 3 Active but recruitment closed Belgium Stage I Pancreatic Cancer AJCC v6 and v7 Infos
NCT01013649 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Interventional Phase 3 Active but recruitment closed Israel Pancreatic Acinar Cell Carcinoma Infos
NCT01013649 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Interventional Phase 3 Active but recruitment closed Israel Pancreatic Ductal Adenocarcinoma Infos
NCT01013649 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Interventional Phase 3 Active but recruitment closed Israel Pancreatic Intraductal Papillary-Mucinous Neoplasm Infos
NCT01013649 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Interventional Phase 3 Active but recruitment closed Israel Stage IA Pancreatic Cancer AJCC v6 and v7 Infos
NCT01013649 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Interventional Phase 3 Active but recruitment closed Israel Stage IB Pancreatic Cancer AJCC v6 and v7 Infos
NCT01013649 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Interventional Phase 3 Active but recruitment closed Israel Stage IIA Pancreatic Cancer AJCC v6 and v7 Infos
NCT01013649 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Interventional Phase 3 Active but recruitment closed Israel Stage IIB Pancreatic Cancer AJCC v6 and v7 Infos
NCT01013649 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Interventional Phase 3 Active but recruitment closed Israel Stage II Pancreatic Cancer AJCC v6 and v7 Infos
NCT01013649 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Interventional Phase 3 Active but recruitment closed Israel Stage I Pancreatic Cancer AJCC v6 and v7 Infos
NCT01027221 Low Dose Radiation to Improve T-Cell Infiltration in Pancreatic Cancer Interventional N/A Unknown status Germany Primarily Resectable Pancreatic Cancer Infos
NCT01037049 Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks Interventional Phase 2 Active but recruitment closed Cyprus Digestive System Neoplasms Infos
NCT01037049 Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks Interventional Phase 2 Active but recruitment closed United Kingdom Digestive System Neoplasms Infos
NCT01038154 Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Interventional Phase 4 Unknown status Spain Esophageal Cancer Infos
NCT01038154 Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Interventional Phase 4 Unknown status Spain Stomach Cancer Infos
NCT01048216 Partial Liver Radiotherapy for Unresectable Liver Metastases Interventional N/A Unknown status United Kingdom Metastatic Colorectal Liver Cancer Infos
NCT01056796 Compression Anastomosis For Low Anterior Resection in Previously Radiated Patients Using the CAR™ 27 Interventional Phase 2 Unknown status Belgium Colorectal Cancer Infos
NCT01062334 Peritoneal Microdialysis in Patients Undergoing Low Anterior Resection for Rectum Cancer Interventional N/A Unknown status Denmark Cancer Infos
NCT01064375 Safety Study of DNA Vaccine Delivered by Intradermal Electroporation to Treat Colorectal Cancer Interventional Phase 1/Phase 2 Unknown status Sweden Colorectal Cancer Infos
NCT01067053 Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients. Interventional Phase 2 Unknown status Spain Metastatic Colorectal Cancer Infos
NCT01071824 Comparison of Limb Size of Transverse Coloplasty Pouch Interventional N/A Recruitment open Switzerland Colon Cancer Infos
NCT01087268 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Interventional Phase 3 Unknown status United Kingdom Colorectal Cancer Infos
NCT01097265 Study of Micrometastases in Patients With Stage I or Stage II Localized Colon Cancer That Can Be Removed by Surgery Interventional Phase 2/Phase 3 Unknown status Netherlands Colorectal Cancer Infos
NCT01106261 A Randomised Trial of Pulmonary Metastasectomy in Colorectal Cancer Interventional N/A Active but recruitment closed Italy Colorectal Cancer Infos
NCT01106261 A Randomised Trial of Pulmonary Metastasectomy in Colorectal Cancer Interventional N/A Active but recruitment closed Italy Pulmonary Metastases Infos
NCT01106261 A Randomised Trial of Pulmonary Metastasectomy in Colorectal Cancer Interventional N/A Active but recruitment closed Serbia Colorectal Cancer Infos
NCT01106261 A Randomised Trial of Pulmonary Metastasectomy in Colorectal Cancer Interventional N/A Active but recruitment closed Serbia Pulmonary Metastases Infos
NCT01106261 A Randomised Trial of Pulmonary Metastasectomy in Colorectal Cancer Interventional N/A Active but recruitment closed United Kingdom Colorectal Cancer Infos
NCT01106261 A Randomised Trial of Pulmonary Metastasectomy in Colorectal Cancer Interventional N/A Active but recruitment closed United Kingdom Pulmonary Metastases Infos
NCT01110785 Simvastatin and Panitumumab in Treating Patients With Advanced or Metastatic Colorectal Cancer Interventional Phase 2 Unknown status Netherlands Colorectal Cancer Infos
NCT01110798 J-Pouch Colorectal Anastomosis or Straight Colorectal Anastomosis in Treating Patients With Rectal Cancer Who Have Undergone Surgery to Remove the Tumor Interventional N/A Unknown status Italy Colorectal Cancer Infos
NCT01116804 Role PET Imaging in Response Assessment for Hepatocellular Carcinoma (HCC) Interventional Phase 1 Unknown status Belgium Primary Liver Cancer Infos
NCT01126463 188RE-SSS Lipiodol to Treat HepatoCellular Carcinomas Interventional Phase 1 Active but recruitment closed France Hepatocellular Carcinomas Infos
NCT01144195 A Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Second Line Treatment in Subjects With Metastatic Colorectal Cancer Expressing Wild-type KRAS and Who Had Progressed ≥ 6 Months After the Last Dose of the First Line Chemotherapy Interventional Phase 2 Unknown status Spain Metastatic Colorectal Cancer Infos
NCT01160419 Multicenter Study to Perioperative Chemotherapy for Resectable Adenocarcinoma in Gastric Cancer Interventional Phase 2 Unknown status Germany Gastric Cancer Infos
NCT01167374 Carbon Ion Radiotherapy for Hepatocellular Carcinoma Interventional N/A Recruitment open Germany Hepatocellular Carcinoma Infos
NCT01182246 AXP107-11 in Combination With Standard Gemcitabine (Gemzar® ) Therapy for Treatment in Patients With Pancreatic Cancer Interventional Phase 1/Phase 2 Unknown status Sweden Adenocarcinoma Infos
NCT01182272 Sorafenib Tosylate in Treating Patients With Liver Cancer That Can Be Removed by Surgery Interventional Phase 2 Unknown status France Liver Cancer Infos
NCT01183156 Re-invitation to Screening Colonoscopy: a Randomized Study Interventional N/A Unknown status Poland Colorectal Cancer Infos
NCT01190462 Cetuximab and Simvastatin in Treating Patients With Advanced or Metastatic Colorectal Cancer Interventional Phase 2 Unknown status Netherlands Colorectal Cancer Infos
NCT01198704 Study of Factors Predicting Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma (HCC) Observational N/A Unknown status France Evidence of Liver Transplantation Infos
NCT01198704 Study of Factors Predicting Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma (HCC) Observational N/A Unknown status France Hepatocellular Carcinoma Infos
NCT01198704 Study of Factors Predicting Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma (HCC) Observational N/A Unknown status France Liver Cirrhosis Infos
NCT01214681 Chemoprevention of Colorectal Cancer: the Role of Non-digestible Carbohydrates Interventional N/A Unknown status United Kingdom Colorectal Cancer Infos
NCT01224392 Simultaneous Integrated Boost Preoperative Radiotherapy for Rectum Cancer Interventional Phase 3 Unknown status Belgium Rectal Cancer Infos
NCT01226394 Trial Comparing Simple Follow-up to Exploratory Laparotomy Plus "in Principle" (Hyperthermic Intraperitoneal Chemotherapy) HIPEC in Colorectal Patients Interventional Phase 3 Unknown status France Colorectal Cancer With a Resected Minimal Synchronous PC Infos
NCT01230697 Perspective Evaluation of Hormones Involved in Serum Phosphate Homeostasis in Patients With Metastatic Renal Cells Carcinoma or Hepatocellular Carcinoma Treated With Sorafenib (SORHORM) Observational N/A Unknown status Italy Kidney Cancer Infos
NCT01230697 Perspective Evaluation of Hormones Involved in Serum Phosphate Homeostasis in Patients With Metastatic Renal Cells Carcinoma or Hepatocellular Carcinoma Treated With Sorafenib (SORHORM) Observational N/A Unknown status Italy Liver Cancer Infos
NCT01234246 Sexual Dysfunction and the Quality of Sexual Life in Patients With Colorectal Cancer and Their Partners. Observational N/A Unknown status Netherlands Colorectal Cancer Patients and Their Partners Infos
NCT01236989 Prognostic Impact of Anatomical Resection Vs. Non-anatomical Resection for HCC Interventional N/A Unknown status Italy Patients Affected by Hepatocellular Carcinoma Infos
NCT01249638 Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC Interventional Phase 3 Unknown status Germany Colorectal Cancer Metastatic Infos
NCT01254591 Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer Interventional N/A Unknown status United Kingdom Breast Cancer Infos
NCT01254591 Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer Interventional N/A Unknown status United Kingdom Colorectal Cancer Infos
NCT01254591 Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer Interventional N/A Unknown status United Kingdom Esophageal Cancer Infos
NCT01254591 Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer Interventional N/A Unknown status United Kingdom Head and Neck Cancer Infos
NCT01254591 Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer Interventional N/A Unknown status United Kingdom Lung Cancer Infos
NCT01272557 Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial Interventional Phase 2 Unknown status Germany Liver Carcinoma Infos
NCT01276574 Epithelial Ovarian Cancer- Staging and Response to Chemotherapy Evaluated by PET/CT Observational N/A Active but recruitment closed Finland Peritoneal Cancer Infos
NCT01279278 Does the Invitation by the General Practitioner Improve Patients' Participation in Colorectal Cancer Screening? Interventional N/A Unknown status France Colorectal Cancer Infos
NCT01279330 Does the Recall by the General Practitioner Improve Patients' Participation in Colorectal Cancer Screening? Interventional N/A Unknown status France Colorectal Cancer Infos
NCT01286064 Colorectal Cancer Detection by Means of Optical Fluoroscopy Interventional N/A Unknown status Italy Colorectal Cancer Infos
NCT01292369 Breath Testing for Breast and Colon Cancer Diagnosis- NaNose Study Observational N/A Unknown status Israel Breast Cancer Infos
NCT01292369 Breath Testing for Breast and Colon Cancer Diagnosis- NaNose Study Observational N/A Unknown status Israel Colon Cancer Infos
NCT01292681 Multi-modality Imaging in the Prediction of Response to Systemic Treatment in Colorectal Cancer Interventional N/A Unknown status Netherlands Colorectal Cancer Infos
NCT01298570 Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer Interventional Phase 2 Active but recruitment closed Ireland Colorectal Cancer Metastatic Infos
NCT01300143 Association of Conformational High-dose Radiotherapy and of Hyperselective Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma Interventional Phase 2 Unknown status France Hepatocellular Carcinoma Infos
NCT01308086 Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer Interventional Phase 3 Unknown status Greece CRC Infos
NCT01315990 FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema Interventional Phase 4 Unknown status Germany Colorectal Cancer Metastatic Infos
NCT01318161 Epidural Versus Patient-controlled Analgesia for Reduction in Long-term Mortality Following Colorectal Cancer Surgery Interventional Phase 3 Recruitment open Sweden Colorectal Cancer Infos
NCT01318161 Epidural Versus Patient-controlled Analgesia for Reduction in Long-term Mortality Following Colorectal Cancer Surgery Interventional Phase 3 Recruitment open Sweden Other Complications Infos
NCT01318161 Epidural Versus Patient-controlled Analgesia for Reduction in Long-term Mortality Following Colorectal Cancer Surgery Interventional Phase 3 Recruitment open Sweden Pain Infos
NCT01320319 Effect of EPA on Aerobic Performance, Muscle, and Quality of Life in Colorectal Cancer Surgery Patients Interventional Phase 2/Phase 3 Unknown status United Kingdom Colorectal Cancer Infos
NCT01322477 Contribution of F-18 Fluoro-Deoxy-Glucose PET/CT (Positron Emission Tomography) to the Assessment of HCC (Hepato-cellular Carcinoma) Treatment Efficiency Observational N/A Unknown status Israel Hepatocellular Carcinoma Infos
NCT01324076 Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery Interventional Phase 3 Unknown status United Kingdom Liver Cancer Infos
NCT01324856 Pancreaticogastrostomy Versus Pancreaticojejunostomy in Reconstruction After Cephalic Duodenopancreatectomy Interventional Phase 1 Unknown status Serbia Pancreatic Cancer Infos
NCT01325961 Medico-economic Evaluation Comparing Intensity-Modulated Radiation Therapy (IMRT) Performed by Helical Tomotherapy and Dynamic Arc Therapy in Prostate, Cervical and Anal Canal Cancers Interventional N/A Unknown status France Anal Canal Cancers Infos
NCT01325961 Medico-economic Evaluation Comparing Intensity-Modulated Radiation Therapy (IMRT) Performed by Helical Tomotherapy and Dynamic Arc Therapy in Prostate, Cervical and Anal Canal Cancers Interventional N/A Unknown status France Cervical Cancer Infos
NCT01325961 Medico-economic Evaluation Comparing Intensity-Modulated Radiation Therapy (IMRT) Performed by Helical Tomotherapy and Dynamic Arc Therapy in Prostate, Cervical and Anal Canal Cancers Interventional N/A Unknown status France Prostate Cancer Infos
NCT01328171 FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI) Interventional Phase 2 Active but recruitment closed Germany Metastatic Colorectal Cancer Infos
NCT01330186 Predictive Value of FMISO-PET, FDG-PET-CT, DWI-MRI and DCE-MRI Scans for Patients With Anal Cancer Receiving Radiotherapy +/- Chemotherapy Observational N/A Unknown status Denmark Anal Cancer Infos
NCT01345526 Efficacy and Safety of the Prophylactic Use of Doxycycline +/- Vitamin K Cream Interventional Phase 2 Unknown status Germany Metastatic Colorectal Cancer Infos
NCT01345526 Efficacy and Safety of the Prophylactic Use of Doxycycline +/- Vitamin K Cream Interventional Phase 2 Unknown status Slovenia Metastatic Colorectal Cancer Infos
NCT01351103 A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Interventional Phase 1 Recruitment open Netherlands BRAF Mutant Colorectal Cancer Infos
NCT01351103 A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Interventional Phase 1 Recruitment open Netherlands Pancreatic Cancer Infos
NCT01351103 A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Interventional Phase 1 Recruitment open Spain BRAF Mutant Colorectal Cancer Infos
NCT01351103 A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Interventional Phase 1 Recruitment open Spain Pancreatic Cancer Infos
NCT01351714 Safe D3 Right Hemicolectomy for Cancer Through Multidetector Computed Tomography (MDCT) Angio Interventional N/A Recruitment open Norway Colon Cancer Infos
NCT01359397 Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer Interventional Phase 2 Unknown status Netherlands Adenocarcinoma of the Gastro-oesophageal Junction Infos
NCT01359397 Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer Interventional Phase 2 Unknown status Netherlands Metastatic Gastric Cancer Infos
NCT01363739 Evaluation of VEGF Polymorphism as Predictive Factor in Metastatic Colorectal Cancer Treated With Folfiri Plus Bevacizumab Observational N/A Unknown status Italy Metastatic Colorectal Cancer Infos
NCT01372735 Trial of Neoadjuvant Short Course IMRT Followed by Surgery and IORT for Resectable Pancreatic Cancer Interventional Phase 1/Phase 2 Unknown status Germany Pancreatic Neoplasms Infos
NCT01377220 Evaluation of 11 C-Choline PET-CT for Detection of Hepatocellular Carcinoma Interventional Phase 2 Unknown status France Hepatocellular Carcinoma Infos
NCT01380262 Pre-emptive Low-dose Doxycycline During Anti-EGFR Treatment Observational N/A Unknown status Poland Colorectal Cancer Infos
NCT01384994 Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients Interventional Phase 2 Unknown status Germany After Resection of Liver Metastases Infos
NCT01384994 Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients Interventional Phase 2 Unknown status Germany Colorectal Cancer Infos
NCT01384994 Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients Interventional Phase 2 Unknown status Germany KRAS Wildtype Infos
NCT01387503 Expansion of Conventional Criteria for Liver Transplantation in Hepatocellular Carcinoma Through Downstaging Interventional Phase 2/Phase 3 Unknown status Italy Carcinoma, Hepatocellular Infos
NCT01387503 Expansion of Conventional Criteria for Liver Transplantation in Hepatocellular Carcinoma Through Downstaging Interventional Phase 2/Phase 3 Unknown status Italy Cirrhosis Infos
NCT01387932 HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer Interventional Phase 3 Active but recruitment closed Austria Hepatocellular Carcinoma Infos
NCT01387932 HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer Interventional Phase 3 Active but recruitment closed Belgium Hepatocellular Carcinoma Infos
NCT01387932 HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer Interventional Phase 3 Active but recruitment closed France Hepatocellular Carcinoma Infos
NCT01387932 HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer Interventional Phase 3 Active but recruitment closed Greece Hepatocellular Carcinoma Infos
NCT01387932 HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer Interventional Phase 3 Active but recruitment closed Italy Hepatocellular Carcinoma Infos
NCT01394120 Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer Interventional Phase 2 Unknown status Spain Carcinoma, Pancreatic Ductal Infos
NCT01397019 Chemotherapy for Patients With Locally Advanced Pancreatic Cancer (LAPC) With Additional Chemo-radiotherapy (CRT) for Patients With Borderline Resectable Tumours Interventional Phase 2 Unknown status Denmark Pancreatic Cancer Infos
NCT01402271 Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer Interventional Phase 1/Phase 2 Active but recruitment closed Belgium Fallopian Tube Cancer Infos
NCT01402271 Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer Interventional Phase 1/Phase 2 Active but recruitment closed Belgium Ovarian Cancer Infos
NCT01402271 Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer Interventional Phase 1/Phase 2 Active but recruitment closed Belgium Primary Peritoneal Cavity Cancer Infos
NCT01402271 Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer Interventional Phase 1/Phase 2 Active but recruitment closed Netherlands Fallopian Tube Cancer Infos
NCT01402271 Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer Interventional Phase 1/Phase 2 Active but recruitment closed Netherlands Ovarian Cancer Infos
NCT01402271 Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer Interventional Phase 1/Phase 2 Active but recruitment closed Netherlands Primary Peritoneal Cavity Cancer Infos
NCT01402271 Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer Interventional Phase 1/Phase 2 Active but recruitment closed Spain Fallopian Tube Cancer Infos
NCT01402271 Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer Interventional Phase 1/Phase 2 Active but recruitment closed Spain Ovarian Cancer Infos
NCT01402271 Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer Interventional Phase 1/Phase 2 Active but recruitment closed Spain Primary Peritoneal Cavity Cancer Infos
NCT01410760 PERfusion CT in the FOXFIRE Trial to Study Blood Flow to Liver Metastases Interventional Early Phase 1 Unknown status United Kingdom Metastatic Colorectal Cancer Infos
NCT01419860 Evaluation of Microcirculation in Colon Wall and Bowel Anastomosis by Laser Induced Fluorescence Video Angiography Interventional Early Phase 1 Unknown status Norway Colon Cancer Infos
NCT01436656 A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma Interventional Phase 1 Active but recruitment closed France Melanoma and Metastatic Colorectal Cancer Infos
NCT01436656 A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma Interventional Phase 1 Active but recruitment closed Norway Melanoma and Metastatic Colorectal Cancer Infos
NCT01436656 A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma Interventional Phase 1 Active but recruitment closed Spain Melanoma and Metastatic Colorectal Cancer Infos
NCT01436656 A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma Interventional Phase 1 Active but recruitment closed Switzerland Melanoma and Metastatic Colorectal Cancer Infos
NCT01441453 Transient Elastography in Hepatectomy for Hepatocellular Carcinoma Interventional N/A Unknown status Italy Hepatocellular Carcinoma Infos
NCT01441453 Transient Elastography in Hepatectomy for Hepatocellular Carcinoma Interventional N/A Unknown status Italy Surgery Infos
NCT01442324 Pilot Study of Irreversible Electroporation (IRE) to Treat Metastatic Liver Cancer & Cholangiocarcinoma Interventional N/A Unknown status Italy Cholangiocarcinoma Infos
NCT01442324 Pilot Study of Irreversible Electroporation (IRE) to Treat Metastatic Liver Cancer & Cholangiocarcinoma Interventional N/A Unknown status Italy Metastatic Liver Cancer Infos
NCT01442324 Pilot Study of Irreversible Electroporation (IRE) to Treat Metastatic Liver Cancer & Cholangiocarcinoma Interventional N/A Unknown status Italy Neoplasm Metastasis Infos
NCT01442649 Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab Interventional Phase 2 Unknown status France Colorectal Cancer Infos
NCT01442935 Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases Interventional Phase 2 Unknown status France Colorectal Cancer Infos
NCT01444755 The Effect of Neoadjuvant Chemotherapy on Locally Advanced Gastric Cancer Observational N/A Unknown status Turkey Gastric Cancer Infos
NCT01448655 Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV) Observational N/A Unknown status Austria Colorectal Cancer Infos
NCT01448655 Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV) Observational N/A Unknown status Germany Colorectal Cancer Infos
NCT01448668 Iscador Qu as Supportive Treatment in Pancreatic Cancer (Union for International Cancer Control, UICC Stages II-IV) Observational N/A Unknown status Austria Pancreas Cancer Infos
NCT01448668 Iscador Qu as Supportive Treatment in Pancreatic Cancer (Union for International Cancer Control, UICC Stages II-IV) Observational N/A Unknown status Germany Pancreas Cancer Infos
NCT01455831 Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colorectal Cancer Interventional Phase 3 Recruitment open Belgium Adenocarcinoma of the Colon Infos
NCT01455831 Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colorectal Cancer Interventional Phase 3 Recruitment open France Adenocarcinoma of the Colon Infos
NCT01456455 Gastric Cancer Metastasized to the Central Nervous System (CNS) Observational N/A Unknown status Switzerland Gastric Cancer Infos
NCT01458353 Microbiological Spectrum of the Intraperitoneal Surface After Elective Right-sided Colon Cancer Interventional Phase 3 Unknown status Spain Intra-abdominal Abscess Infos
NCT01458353 Microbiological Spectrum of the Intraperitoneal Surface After Elective Right-sided Colon Cancer Interventional Phase 3 Unknown status Spain Peritoneal Contamination After Ileocolonic Anastomosis Infos
NCT01458353 Microbiological Spectrum of the Intraperitoneal Surface After Elective Right-sided Colon Cancer Interventional Phase 3 Unknown status Spain Wound Infection Infos
NCT01464151 Risk Factors for Colorectal Cancer in Patients With Inflammatory Bowel Disease Undergoing Surveillance: a Prospective Cohort Study Observational N/A Active but recruitment closed Netherlands Colorectal Cancer Infos
NCT01464151 Risk Factors for Colorectal Cancer in Patients With Inflammatory Bowel Disease Undergoing Surveillance: a Prospective Cohort Study Observational N/A Active but recruitment closed Netherlands Inflammatory Bowel Disease Infos
NCT01470235 Hypodontia and Ovarian Cancer Observational N/A Unknown status Denmark Colon Cancer Infos
NCT01479608 Liver Transplantation and Colorectal Cancer Interventional Phase 2 Recruitment open Norway Colorectal Cancer Infos
NCT01479608 Liver Transplantation and Colorectal Cancer Interventional Phase 2 Recruitment open Norway Liver Metastasis Infos
NCT01483027 Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer Interventional Phase 3 Active but recruitment closed Austria Colorectal Cancer Metastatic Infos
NCT01483027 Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer Interventional Phase 3 Active but recruitment closed Belgium Colorectal Cancer Metastatic Infos
NCT01483027 Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer Interventional Phase 3 Active but recruitment closed Czechia Colorectal Cancer Metastatic Infos
NCT01483027 Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer Interventional Phase 3 Active but recruitment closed France Colorectal Cancer Metastatic Infos
NCT01483027 Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer Interventional Phase 3 Active but recruitment closed Germany Colorectal Cancer Metastatic Infos
NCT01483027 Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer Interventional Phase 3 Active but recruitment closed Italy Colorectal Cancer Metastatic Infos
NCT01483027 Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer Interventional Phase 3 Active but recruitment closed Poland Colorectal Cancer Metastatic Infos
NCT01483027 Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer Interventional Phase 3 Active but recruitment closed Spain Colorectal Cancer Metastatic Infos
NCT01483027 Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer Interventional Phase 3 Active but recruitment closed United Kingdom Colorectal Cancer Metastatic Infos
NCT01492127 Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment Interventional N/A Unknown status France Cirrhosis Infos
NCT01492127 Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment Interventional N/A Unknown status France Hepatocellular Carcinoma Infos
NCT01509911 A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine Treatment Interventional Phase 2 Unknown status Israel Metastatic Pancreatic Cancer Infos
NCT01515787 PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery Interventional Phase 2/Phase 3 Active but recruitment closed Israel Colorectal Cancer Infos
NCT01515787 PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery Interventional Phase 2/Phase 3 Active but recruitment closed Switzerland Colorectal Cancer Infos
NCT01531595 Study of Bevacizumab in Combination With Alternating Xeliri and Xelox in Metastatic Colorectal Cancer Interventional Phase 2 Recruitment open Finland Metastatic Colorectal Cancer Infos
NCT01531621 A Population-based Prospective Study of Metastatic Colorectal Cancer (CRC) Patients in Finland Observational N/A Recruitment open Finland Metastatic Colorectal Cancer Infos
NCT01538550 Pilot Study of a National Screening Programme for Bowel Cancer in Norway Interventional N/A Active but recruitment closed Norway Colorectal Cancer Infos
NCT01556490 Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer Interventional Phase 3 Active but recruitment closed Belgium Unresectable Hepatocellular Carcinoma Infos
NCT01556490 Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer Interventional Phase 3 Active but recruitment closed France Unresectable Hepatocellular Carcinoma Infos
NCT01556490 Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer Interventional Phase 3 Active but recruitment closed Germany Unresectable Hepatocellular Carcinoma Infos
NCT01556490 Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer Interventional Phase 3 Active but recruitment closed Italy Unresectable Hepatocellular Carcinoma Infos
NCT01556490 Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer Interventional Phase 3 Active but recruitment closed Netherlands Unresectable Hepatocellular Carcinoma Infos
NCT01556490 Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer Interventional Phase 3 Active but recruitment closed Spain Unresectable Hepatocellular Carcinoma Infos
NCT01556490 Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer Interventional Phase 3 Active but recruitment closed United Kingdom Unresectable Hepatocellular Carcinoma Infos
NCT01563133 Clinical Evaluation Of Needle-based Confocal Laser Endomicroscopy in The Lymph Nodes Along With Masses and Cystic Tumors of the Pancreas Interventional N/A Unknown status France Pancreatic Cancer Infos
NCT01570010 Effect of the New Norwegian Food Based Dietary Guidelines on Chronic Diseases in Colorectal Cancer Survivors Interventional N/A Recruitment open Norway Colorectal Cancer Infos
NCT01573468 Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer Interventional Phase 2 Unknown status Germany Gastric Carcinoma Infos
NCT01577511 Invasiveness and Chemoresistance of Cancer Stem Cells in Colon Cancer Observational N/A Unknown status France Colorectal Neoplasms Infos
NCT01585805 Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Interventional Phase 2 Active but recruitment closed Israel Metastatic Pancreatic Adenocarcinoma Infos
NCT01585805 Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Interventional Phase 2 Active but recruitment closed Israel Recurrent Pancreatic Carcinoma Infos
NCT01585805 Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Interventional Phase 2 Active but recruitment closed Israel Stage III Pancreatic Cancer AJCC v6 and v7 Infos
NCT01585805 Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Interventional Phase 2 Active but recruitment closed Israel Stage IV Pancreatic Cancer AJCC v6 and v7 Infos
NCT01589146 ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER. Interventional Phase 3 Unknown status Italy From Surgery in the Two Study Groups. Infos
NCT01589146 ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER. Interventional Phase 3 Unknown status Italy Prophylaxis Given for 8±2 Days After Planned Laparoscopic Infos
NCT01589146 ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER. Interventional Phase 3 Unknown status Italy Safety of Extended 4-week Heparin Prophylaxis Compared to Infos
NCT01589146 ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER. Interventional Phase 3 Unknown status Italy Surgery for Colorectal Cancer. Infos
NCT01589146 ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER. Interventional Phase 3 Unknown status Italy The Clinical Benefit Will be Evaluated as the Difference in Infos
NCT01589146 ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER. Interventional Phase 3 Unknown status Italy the Incidence of VTE or VTE-related Death Occurring Within 30 Days Infos
NCT01589146 ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER. Interventional Phase 3 Unknown status Italy The Primary Study Objective is to Assess the Efficacy and Infos
NCT01591590 Correlating the Tumoral Metabolic Progression Index to Patient's Outcome in Advanced Colorectal Cancer Interventional N/A Active but recruitment closed Belgium Colorectal Cancer Infos
NCT01601808 Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma Interventional Phase 2 Unknown status United Kingdom Pancreatic Cancer Infos
NCT01604564 Registry With Information About Colitis Ulcerosa and Familial Adenomatous Polyposis Patients Observational N/A Active but recruitment closed Belgium Adenomatous Polyposis Coli Infos
NCT01604564 Registry With Information About Colitis Ulcerosa and Familial Adenomatous Polyposis Patients Observational N/A Active but recruitment closed Belgium Colitis,Ulcerative Infos
NCT01604564 Registry With Information About Colitis Ulcerosa and Familial Adenomatous Polyposis Patients Observational N/A Active but recruitment closed Belgium Reservoir, Ileoanal Infos
NCT01606098 The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal Cancer Interventional Phase 3 Recruitment open Denmark Colon Cancer Infos
NCT01606098 The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal Cancer Interventional Phase 3 Recruitment open Denmark Primary Tumour Infos
NCT01606098 The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal Cancer Interventional Phase 3 Recruitment open Denmark Rectal Cancer Infos
NCT01606098 The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal Cancer Interventional Phase 3 Recruitment open Netherlands Colon Cancer Infos
NCT01606098 The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal Cancer Interventional Phase 3 Recruitment open Netherlands Primary Tumour Infos
NCT01606098 The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal Cancer Interventional Phase 3 Recruitment open Netherlands Rectal Cancer Infos
NCT01626963 Single-port Versus Conventional Laparoscopic Colorectal Surgery Interventional Phase 1/Phase 2 Unknown status United Kingdom Colorectal Cancer Infos
NCT01628211 Second Look Laparoscopy in Colorectal Cancer Interventional Phase 2 Unknown status Italy Colorectal Cancer Infos
NCT01639326 Study to Evaluate the Efficacy and Safety of FOLFIRI-AD in Patients With Metastatic Colorectal Cancer UGT1A Genotype 1 Interventional Phase 2 Unknown status Spain Metastatic Colorectal Cancer Infos
NCT01641003 Isolation and Characterization of Cancer Stem Cells Using iFP Technique Observational N/A Unknown status Israel Pancreatic Cancer Infos
NCT01642875 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy Interventional Phase 4 Recruitment open Poland Pancreatic Cancer Infos
NCT01651013 Observational Study on Treatment of Metastatic Colorectal Cancer and the Role of K-Ras Observational N/A Unknown status Italy Metastatic Colorectal Cancer Infos
NCT01651026 Multicenter Cohort Prospective Study on Multidisciplinary Treatment of Rectal Cancer Observational N/A Unknown status Italy Metastatic Colorectal Cancer Infos
NCT01658878 An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer Interventional Phase 1/Phase 2 Active but recruitment closed France Hepatocellular Carcinoma Infos
NCT01658878 An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer Interventional Phase 1/Phase 2 Active but recruitment closed Germany Hepatocellular Carcinoma Infos
NCT01658878 An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer Interventional Phase 1/Phase 2 Active but recruitment closed Italy Hepatocellular Carcinoma Infos
NCT01658878 An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer Interventional Phase 1/Phase 2 Active but recruitment closed Spain Hepatocellular Carcinoma Infos
NCT01658878 An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer Interventional Phase 1/Phase 2 Active but recruitment closed United Kingdom Hepatocellular Carcinoma Infos
NCT01659502 Investigator's Initiated Phase II Study for Pancreatic Cancer Patients Interventional Phase 2 Unknown status Israel Pancreatic Cancer Infos
NCT01662739 Cremona Population-Based Gastric Tumors Registry Observational N/A Unknown status Italy Gastric Cancer Infos
NCT01673607 Study of Immune Response and Liver Damage Induced by Chemotherapy for Liver Metastases of Colorectal Cancer Interventional Phase 2 Recruitment open France Resectable Hepatic Metastases of Colorectal Cancer Infos
NCT01675258 Identifying Saliva Markers of Patients With Stomach, Colorectal (Including Pre-cancer Polyp) and Pancreatic Cancers Observational N/A Unknown status Israel Colorectal Cancer and Pre-cancer Polyps Infos
NCT01675258 Identifying Saliva Markers of Patients With Stomach, Colorectal (Including Pre-cancer Polyp) and Pancreatic Cancers Observational N/A Unknown status Israel Gastric Cancer Infos
NCT01675258 Identifying Saliva Markers of Patients With Stomach, Colorectal (Including Pre-cancer Polyp) and Pancreatic Cancers Observational N/A Unknown status Israel Pancreatic Cancer Infos
NCT01675505 Psychological Well-being Outcomes in Disease-free Survivors of Colorectal Cancer Following Curative Surgery Observational N/A Unknown status Greece Adaptation, Psychological Infos
NCT01675505 Psychological Well-being Outcomes in Disease-free Survivors of Colorectal Cancer Following Curative Surgery Observational N/A Unknown status Greece Functional Insufficiency Infos
NCT01675999 Trial of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer Interventional Phase 2 Recruitment open France Colon Cancer Infos
NCT01675999 Trial of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer Interventional Phase 2 Recruitment open France Locally Advanced Malignant Neoplasm Infos
NCT01676259 A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer Interventional Phase 2 Recruitment open Israel Pancreatic Cancer Infos
NCT01676259 A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer Interventional Phase 2 Recruitment open Israel Pancreatic Ductal Adenocarcinoma Infos
NCT01679756 INtracorporeal Versus EXTracorpoREal anastoMOsis After Laparoscopic Right Colectomy for Cancer Interventional N/A Unknown status Italy Colorectal Cancer Infos
NCT01686971 The Needs of Cancer Survivors Observational N/A Unknown status Israel Colon Cancer Patients. Infos
NCT01688232 The Immunoscore as a Prognostic Marker for Patients With a Colorectal Cancer Observational N/A Unknown status France Colorectal Cancer Infos
NCT01688232 The Immunoscore as a Prognostic Marker for Patients With a Colorectal Cancer Observational N/A Unknown status France Surgical Resection of the Colorectal Tumor Infos
NCT01694277 Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib Interventional Phase 3 Active but recruitment closed France Gastrointestinal Stromal Tumors Infos
NCT01694277 Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib Interventional Phase 3 Active but recruitment closed Italy Gastrointestinal Stromal Tumors Infos
NCT01694277 Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib Interventional Phase 3 Active but recruitment closed Netherlands Gastrointestinal Stromal Tumors Infos
NCT01703390 Biomarker Directed Treatment in Metastatic Colorectal Cancer Interventional Phase 2 Active but recruitment closed Austria Metastatic Colorectal Cancer Infos
NCT01704664 Perioperative Immunonutrition, Phagocytic and Bactericidal Activity of Blood Platelets in Gastric Cancer Patients Interventional N/A Recruitment open Poland Gastric Cancer Infos
NCT01706809 Comparing of Different Biomarkers From Vena Rectalis Superior and Vena Cubiti in Patients Undergoing Low Anterior Resection for Rectum Cancer Observational N/A Unknown status Denmark Rectal Cancer Infos
NCT01707511 The Investigation of the EtCO₂- PaCO₂ Relation During Laparoscopic Colon Surgery Observational N/A Unknown status Turkey Colorectal Cancer Infos
NCT01713218 Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer Interventional Early Phase 1 Unknown status Belgium Pancreatic Adenocarcinoma Resectable Infos
NCT01715402 Optimization of Health Expenditure in Liver Surgery Observational N/A Unknown status France Hepatocellular Carcinoma Infos
NCT01717196 Diagnostic Accuracy of FNA: is Aspiration- Related? Interventional N/A Unknown status Italy PANCREATIC CANCER Infos
NCT01717807 C11-Erlotinib PET/CT as a Tool for Identification and Characterization of Tumor With High Expression of Epidermal Growth Factor Receptor(EGFR). Observational N/A Unknown status Israel Pancreatic Cancer Infos
NCT01718873 Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal Cancer Interventional Phase 3 Unknown status Italy Colorectal Cancer Infos
NCT01723969 Screening Platform for Clinical Trials in Advanced Colorectal Cancer Observational N/A Active but recruitment closed Belgium Advanced Colorectal Cancer Infos
NCT01723969 Screening Platform for Clinical Trials in Advanced Colorectal Cancer Observational N/A Active but recruitment closed Belgium Colorectal Cancer Infos
NCT01723969 Screening Platform for Clinical Trials in Advanced Colorectal Cancer Observational N/A Active but recruitment closed Cyprus Advanced Colorectal Cancer Infos
NCT01723969 Screening Platform for Clinical Trials in Advanced Colorectal Cancer Observational N/A Active but recruitment closed Cyprus Colorectal Cancer Infos
NCT01723969 Screening Platform for Clinical Trials in Advanced Colorectal Cancer Observational N/A Active but recruitment closed France Advanced Colorectal Cancer Infos
NCT01723969 Screening Platform for Clinical Trials in Advanced Colorectal Cancer Observational N/A Active but recruitment closed France Colorectal Cancer Infos
NCT01723969 Screening Platform for Clinical Trials in Advanced Colorectal Cancer Observational N/A Active but recruitment closed Germany Advanced Colorectal Cancer Infos
NCT01723969 Screening Platform for Clinical Trials in Advanced Colorectal Cancer Observational N/A Active but recruitment closed Germany Colorectal Cancer Infos
NCT01723969 Screening Platform for Clinical Trials in Advanced Colorectal Cancer Observational N/A Active but recruitment closed Greece Advanced Colorectal Cancer Infos
NCT01723969 Screening Platform for Clinical Trials in Advanced Colorectal Cancer Observational N/A Active but recruitment closed Greece Colorectal Cancer Infos
NCT01723969 Screening Platform for Clinical Trials in Advanced Colorectal Cancer Observational N/A Active but recruitment closed Italy Advanced Colorectal Cancer Infos
NCT01723969 Screening Platform for Clinical Trials in Advanced Colorectal Cancer Observational N/A Active but recruitment closed Italy Colorectal Cancer Infos
NCT01723969 Screening Platform for Clinical Trials in Advanced Colorectal Cancer Observational N/A Active but recruitment closed Poland Advanced Colorectal Cancer Infos
NCT01723969 Screening Platform for Clinical Trials in Advanced Colorectal Cancer Observational N/A Active but recruitment closed Poland Colorectal Cancer Infos
NCT01723969 Screening Platform for Clinical Trials in Advanced Colorectal Cancer Observational N/A Active but recruitment closed Portugal Advanced Colorectal Cancer Infos
NCT01723969 Screening Platform for Clinical Trials in Advanced Colorectal Cancer Observational N/A Active but recruitment closed Portugal Colorectal Cancer Infos
NCT01723969 Screening Platform for Clinical Trials in Advanced Colorectal Cancer Observational N/A Active but recruitment closed Spain Advanced Colorectal Cancer Infos
NCT01723969 Screening Platform for Clinical Trials in Advanced Colorectal Cancer Observational N/A Active but recruitment closed Spain Colorectal Cancer Infos
NCT01723969 Screening Platform for Clinical Trials in Advanced Colorectal Cancer Observational N/A Active but recruitment closed Sweden Advanced Colorectal Cancer Infos
NCT01723969 Screening Platform for Clinical Trials in Advanced Colorectal Cancer Observational N/A Active but recruitment closed Sweden Colorectal Cancer Infos
NCT01723969 Screening Platform for Clinical Trials in Advanced Colorectal Cancer Observational N/A Active but recruitment closed Switzerland Advanced Colorectal Cancer Infos
NCT01723969 Screening Platform for Clinical Trials in Advanced Colorectal Cancer Observational N/A Active but recruitment closed Switzerland Colorectal Cancer Infos
NCT01726010 22-G-Procore Needle for the Diagnosis of SETs of the Upper GI Tract Interventional N/A Unknown status Germany Subepithelial Tumors of the Upper Gastrointestinal Tract Infos
NCT01726309 Single Nucleotide Polymorphism(SNP)Study. ICORG 08-40, V4 Observational N/A Active but recruitment closed Ireland Colorectal Cancer Infos
NCT01726452 NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS) Interventional Phase 3 Recruitment open Denmark Oesophageal Cancer Infos
NCT01726452 NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS) Interventional Phase 3 Recruitment open France Oesophageal Cancer Infos
NCT01726452 NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS) Interventional Phase 3 Recruitment open Ireland Oesophageal Cancer Infos
NCT01726452 NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS) Interventional Phase 3 Recruitment open United Kingdom Oesophageal Cancer Infos
NCT01729481 Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer Interventional Phase 2 Unknown status Germany Metastatic Pancreatic Adenocarcinoma Infos
NCT01731366 The Effect of Whole Grain on Gut Microbiome and Metabolic Health Interventional N/A Unknown status Denmark Injury of Gastrointestinal Tract Infos
NCT01744509 PillCam Colon Capsule 2® (PCC2) in the Setting of Colorectal Cancer Screening Program Interventional N/A Unknown status Italy Colon Cancer Infos
NCT01754272 A Non-Interventional Follow-Up to the VELOUR Study - Translational Research Observational N/A Unknown status Austria Metastatic Colorectal Cancer Infos
NCT01754272 A Non-Interventional Follow-Up to the VELOUR Study - Translational Research Observational N/A Unknown status Belgium Metastatic Colorectal Cancer Infos
NCT01754272 A Non-Interventional Follow-Up to the VELOUR Study - Translational Research Observational N/A Unknown status Denmark Metastatic Colorectal Cancer Infos
NCT01754272 A Non-Interventional Follow-Up to the VELOUR Study - Translational Research Observational N/A Unknown status Estonia Metastatic Colorectal Cancer Infos
NCT01754272 A Non-Interventional Follow-Up to the VELOUR Study - Translational Research Observational N/A Unknown status Germany Metastatic Colorectal Cancer Infos
NCT01754272 A Non-Interventional Follow-Up to the VELOUR Study - Translational Research Observational N/A Unknown status Greece Metastatic Colorectal Cancer Infos
NCT01754272 A Non-Interventional Follow-Up to the VELOUR Study - Translational Research Observational N/A Unknown status Italy Metastatic Colorectal Cancer Infos
NCT01754272 A Non-Interventional Follow-Up to the VELOUR Study - Translational Research Observational N/A Unknown status Netherlands Metastatic Colorectal Cancer Infos
NCT01754272 A Non-Interventional Follow-Up to the VELOUR Study - Translational Research Observational N/A Unknown status Norway Metastatic Colorectal Cancer Infos
NCT01754272 A Non-Interventional Follow-Up to the VELOUR Study - Translational Research Observational N/A Unknown status Romania Metastatic Colorectal Cancer Infos
NCT01754272 A Non-Interventional Follow-Up to the VELOUR Study - Translational Research Observational N/A Unknown status Russian Federation Metastatic Colorectal Cancer Infos
NCT01754272 A Non-Interventional Follow-Up to the VELOUR Study - Translational Research Observational N/A Unknown status Spain Metastatic Colorectal Cancer Infos
NCT01754272 A Non-Interventional Follow-Up to the VELOUR Study - Translational Research Observational N/A Unknown status Sweden Metastatic Colorectal Cancer Infos
NCT01754272 A Non-Interventional Follow-Up to the VELOUR Study - Translational Research Observational N/A Unknown status United Kingdom Metastatic Colorectal Cancer Infos
NCT01761097 Endocuff Adenoma Detection Rate Pilot Study Interventional N/A Unknown status United Kingdom Colorectal Cancer Infos
NCT01761266 A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma Interventional Phase 3 Active but recruitment closed Belgium Hepatocellular Carcinoma (HCC) Infos
NCT01761266 A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma Interventional Phase 3 Active but recruitment closed France Hepatocellular Carcinoma (HCC) Infos
NCT01761266 A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma Interventional Phase 3 Active but recruitment closed Germany Hepatocellular Carcinoma (HCC) Infos
NCT01761266 A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma Interventional Phase 3 Active but recruitment closed Israel Hepatocellular Carcinoma (HCC) Infos
NCT01761266 A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma Interventional Phase 3 Active but recruitment closed Italy Hepatocellular Carcinoma (HCC) Infos
NCT01761266 A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma Interventional Phase 3 Active but recruitment closed Poland Hepatocellular Carcinoma (HCC) Infos
NCT01761266 A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma Interventional Phase 3 Active but recruitment closed Russian Federation Hepatocellular Carcinoma (HCC) Infos
NCT01761266 A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma Interventional Phase 3 Active but recruitment closed Spain Hepatocellular Carcinoma (HCC) Infos
NCT01761266 A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma Interventional Phase 3 Active but recruitment closed United Kingdom Hepatocellular Carcinoma (HCC) Infos
NCT01762813 Assessment of Clinically Related Outcomes and Biomarker Analysis for Translational Integration in Colorectal Cancer Observational N/A Recruitment open Norway Colorectal Cancer Infos
NCT01779583 Circulating Exosomes As Potential Prognostic And Predictive Biomarkers In Advanced Gastric Cancer Patients ("EXO-PPP Study") Observational N/A Unknown status Spain Gastric Cancer Infos
NCT01786122 Clinical Trial: Effectiveness and Efficiency of Physical Exercise in Cancer Patients Interventional N/A Unknown status Spain Digestive System Neoplasms Infos
NCT01786200 Physiological Effects of Altering Cancer-related Inflammation Interventional N/A Unknown status United Kingdom Colon Cancer Infos
NCT01787539 The Role of Postoperative Cycles in the Perioperative Chemotherapy for Gastric Cancer Interventional Phase 2/Phase 3 Recruitment open Poland Gastric Cancer Infos
NCT01792934 Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases Interventional N/A Recruitment open Netherlands Multi-organ Metastatic Colorectal Cancer Infos
NCT01795768 Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours Interventional Phase 2 Unknown status United Kingdom Gastric Cancer Infos
NCT01795768 Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours Interventional Phase 2 Unknown status United Kingdom Oesophageal Cancer Infos
NCT01798173 Environmental, Metabolic and Nutritional Factors of Hepatocellular Carcinoma in Cirrhotic Patients Interventional N/A Unknown status France Cirrhosis With Hepatocellular Carcinoma Infos
NCT01798173 Environmental, Metabolic and Nutritional Factors of Hepatocellular Carcinoma in Cirrhotic Patients Interventional N/A Unknown status France Cirrhosis Without Hepatocellular Carcinoma Infos
NCT01801904 A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer Interventional Phase 2 Unknown status Italy Metastatic Colorectal Cancer Infos
NCT01802645 Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases Interventional Phase 2 Active but recruitment closed Germany Colorectal Cancer Infos
NCT01814150 The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With Docetaxel Observational N/A Unknown status Israel Metastatic Gastric Cancer Infos
NCT01827553 Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy Interventional Phase 3 Recruitment open Germany Pancreatic Cancer Infos
NCT01843829 A Feasibility Study of Chemo-radiotherapy to Treat Operable Oesophageal Cancer Interventional Phase 2 Unknown status United Kingdom Oesophageal Cancer Infos
NCT01845337 Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine Interventional Phase 2 Active but recruitment closed United Kingdom Gastrointestinal Cancer Infos
NCT01845337 Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine Interventional Phase 2 Active but recruitment closed United Kingdom Pancreatic Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Austria Low-grade Serous Fallopian Tube Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Austria Low-grade Serous Ovarian Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Austria Low-grade Serous Peritoneal Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Belgium Low-grade Serous Fallopian Tube Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Belgium Low-grade Serous Ovarian Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Belgium Low-grade Serous Peritoneal Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Czechia Low-grade Serous Fallopian Tube Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Czechia Low-grade Serous Ovarian Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Czechia Low-grade Serous Peritoneal Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Denmark Low-grade Serous Fallopian Tube Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Denmark Low-grade Serous Ovarian Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Denmark Low-grade Serous Peritoneal Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Finland Low-grade Serous Fallopian Tube Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Finland Low-grade Serous Ovarian Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Finland Low-grade Serous Peritoneal Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed France Low-grade Serous Fallopian Tube Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed France Low-grade Serous Ovarian Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed France Low-grade Serous Peritoneal Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Germany Low-grade Serous Fallopian Tube Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Germany Low-grade Serous Ovarian Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Germany Low-grade Serous Peritoneal Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Hungary Low-grade Serous Fallopian Tube Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Hungary Low-grade Serous Ovarian Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Hungary Low-grade Serous Peritoneal Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Ireland Low-grade Serous Fallopian Tube Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Ireland Low-grade Serous Ovarian Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Ireland Low-grade Serous Peritoneal Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Italy Low-grade Serous Fallopian Tube Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Italy Low-grade Serous Ovarian Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Italy Low-grade Serous Peritoneal Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Luxembourg Low-grade Serous Fallopian Tube Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Luxembourg Low-grade Serous Ovarian Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Luxembourg Low-grade Serous Peritoneal Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Netherlands Low-grade Serous Fallopian Tube Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Netherlands Low-grade Serous Ovarian Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Netherlands Low-grade Serous Peritoneal Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Norway Low-grade Serous Fallopian Tube Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Norway Low-grade Serous Ovarian Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Norway Low-grade Serous Peritoneal Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Poland Low-grade Serous Fallopian Tube Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Poland Low-grade Serous Ovarian Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Poland Low-grade Serous Peritoneal Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Spain Low-grade Serous Fallopian Tube Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Spain Low-grade Serous Ovarian Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Spain Low-grade Serous Peritoneal Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Sweden Low-grade Serous Fallopian Tube Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Sweden Low-grade Serous Ovarian Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Sweden Low-grade Serous Peritoneal Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed United Kingdom Low-grade Serous Fallopian Tube Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed United Kingdom Low-grade Serous Ovarian Cancer Infos
NCT01849874 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Interventional Phase 3 Active but recruitment closed United Kingdom Low-grade Serous Peritoneal Cancer Infos
NCT01853059 Functional Outcomes Following Anal Cancer Treatment Observational N/A Unknown status United Kingdom Anal Cancer Infos
NCT01858649 Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI. Interventional Phase 2 Unknown status Belgium Metastatic Colorectal Cancer Infos
NCT01867697 Nordic 8 - A Phase II Trial Interventional Phase 2 Unknown status Denmark Metastatic Colorectal Cancer Infos
NCT01867697 Nordic 8 - A Phase II Trial Interventional Phase 2 Unknown status Norway Metastatic Colorectal Cancer Infos
NCT01867697 Nordic 8 - A Phase II Trial Interventional Phase 2 Unknown status Sweden Metastatic Colorectal Cancer Infos
NCT01876901 Efficacy of Delayed Coloanal Anastomosis for Medium and Lower Rectum Cancer Treatment. Phase 2 Clinical Trial (CASCADOR) Interventional Phase 2 Unknown status France Medium and Lower Rectal Cancer Infos
NCT01879878 Pilot Study Evaluating Broccoli Sprouts in Advanced Pancreatic Cancer [POUDER Trial] Interventional N/A Unknown status Germany Pancreatic Ductal Adenocarcinoma Infos
NCT01885702 Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSI Interventional Phase 1/Phase 2 Active but recruitment closed Netherlands Colorectal Cancer Infos
NCT01891344 A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) Interventional Phase 2 Active but recruitment closed France Epithelial Ovarian Cancer Infos
NCT01891344 A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) Interventional Phase 2 Active but recruitment closed France Fallopian Tube Cancer Infos
NCT01891344 A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) Interventional Phase 2 Active but recruitment closed France Ovarian Cancer Infos
NCT01891344 A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) Interventional Phase 2 Active but recruitment closed France Peritoneal Cancer Infos
NCT01891344 A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) Interventional Phase 2 Active but recruitment closed Spain Epithelial Ovarian Cancer Infos
NCT01891344 A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) Interventional Phase 2 Active but recruitment closed Spain Fallopian Tube Cancer Infos
NCT01891344 A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) Interventional Phase 2 Active but recruitment closed Spain Ovarian Cancer Infos
NCT01891344 A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) Interventional Phase 2 Active but recruitment closed Spain Peritoneal Cancer Infos
NCT01891344 A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) Interventional Phase 2 Active but recruitment closed United Kingdom Epithelial Ovarian Cancer Infos
NCT01891344 A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) Interventional Phase 2 Active but recruitment closed United Kingdom Fallopian Tube Cancer Infos
NCT01891344 A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) Interventional Phase 2 Active but recruitment closed United Kingdom Ovarian Cancer Infos
NCT01891344 A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) Interventional Phase 2 Active but recruitment closed United Kingdom Peritoneal Cancer Infos
NCT01891539 Observational Prospective Study on Chemoembolization With Doxorubicin for Unresectable Hepatocellular Carcinoma Observational N/A Recruitment open Italy Liver Cell Carcinoma Non-resectable Infos
NCT01892527 Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects Interventional Phase 2 Unknown status Italy Colorectal Cancer Metastatic Infos
NCT01895257 Comparing HAI-90Y (SIR-spheres)+Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone to Treat Colorectal Cancer Interventional Phase 3 Unknown status Belgium Colorectal Cancer Infos
NCT01896531 A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Interventional Phase 2 Active but recruitment closed France Gastric Cancer Infos
NCT01896531 A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Interventional Phase 2 Active but recruitment closed Germany Gastric Cancer Infos
NCT01896531 A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Interventional Phase 2 Active but recruitment closed Italy Gastric Cancer Infos
NCT01896531 A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Interventional Phase 2 Active but recruitment closed Spain Gastric Cancer Infos
NCT01896531 A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Interventional Phase 2 Active but recruitment closed United Kingdom Gastric Cancer Infos
NCT01898104 Preoperative Valproic Acid and Radiation Therapy for Rectal Cancer Interventional Phase 1/Phase 2 Unknown status Italy Colorectal Cancer Infos
NCT01898741 Cone-beam CT Guided Stereotactic Radiation Therapy for Locally Advanced Pancreatic Cancer Interventional Phase 2 Unknown status Netherlands Pancreatic Cancer Infos
NCT01899599 PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer Interventional Phase 2 Unknown status Germany Primary Peritoneal Cancer Infos
NCT01899599 PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer Interventional Phase 2 Unknown status Hungary Primary Peritoneal Cancer Infos
NCT01899599 PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer Interventional Phase 2 Unknown status Italy Primary Peritoneal Cancer Infos
NCT01899599 PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer Interventional Phase 2 Unknown status Poland Primary Peritoneal Cancer Infos
NCT01899599 PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer Interventional Phase 2 Unknown status Romania Primary Peritoneal Cancer Infos
NCT01899599 PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer Interventional Phase 2 Unknown status Russian Federation Primary Peritoneal Cancer Infos
NCT01899599 PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer Interventional Phase 2 Unknown status Spain Primary Peritoneal Cancer Infos
NCT01899599 PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer Interventional Phase 2 Unknown status United Kingdom Primary Peritoneal Cancer Infos
NCT01908426 Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib Interventional Phase 3 Active but recruitment closed Belgium Hepatocellular Carcinoma Infos
NCT01908426 Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib Interventional Phase 3 Active but recruitment closed France Hepatocellular Carcinoma Infos
NCT01908426 Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib Interventional Phase 3 Active but recruitment closed Georgia Hepatocellular Carcinoma Infos
NCT01908426 Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib Interventional Phase 3 Active but recruitment closed Germany Hepatocellular Carcinoma Infos
NCT01908426 Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib Interventional Phase 3 Active but recruitment closed Ireland Hepatocellular Carcinoma Infos
NCT01908426 Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib Interventional Phase 3 Active but recruitment closed Italy Hepatocellular Carcinoma Infos
NCT01908426 Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib Interventional Phase 3 Active but recruitment closed Netherlands Hepatocellular Carcinoma Infos
NCT01908426 Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib Interventional Phase 3 Active but recruitment closed Poland Hepatocellular Carcinoma Infos
NCT01908426 Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib Interventional Phase 3 Active but recruitment closed Romania Hepatocellular Carcinoma Infos
NCT01908426 Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib Interventional Phase 3 Active but recruitment closed Spain Hepatocellular Carcinoma Infos
NCT01908426 Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib Interventional Phase 3 Active but recruitment closed Turkey Hepatocellular Carcinoma Infos
NCT01908426 Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib Interventional Phase 3 Active but recruitment closed United Kingdom Hepatocellular Carcinoma Infos
NCT01910610 Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer Interventional Phase 3 Recruitment open France Colorectal Cancer Metastatic Infos
NCT01910610 Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer Interventional Phase 3 Recruitment open Ireland Colorectal Cancer Metastatic Infos
NCT01910610 Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer Interventional Phase 3 Recruitment open Israel Colorectal Cancer Metastatic Infos
NCT01918527 Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer Interventional Phase 3 Recruitment open Denmark Colon Cancer Infos
NCT01918527 Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer Interventional Phase 3 Recruitment open Norway Colon Cancer Infos
NCT01918527 Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer Interventional Phase 3 Recruitment open Sweden Colon Cancer Infos
NCT01919151 Micrometastasis in Gastrointestinal Cancer Observational N/A Unknown status Norway Colorectal Cancer Infos
NCT01919151 Micrometastasis in Gastrointestinal Cancer Observational N/A Unknown status Norway Pancreatic Adenocarcinoma Infos
NCT01927328 Iron Replacement in Oesophagogastric Neoplasia Interventional Phase 4 Unknown status United Kingdom Gastric Cancer Infos
NCT01937429 Effectiveness of Instillation of Blue Water (Indigo Carmin®) for Colonoscopy Interventional Phase 3 Unknown status France Adenoma Detection to Prevent Colorectal Cancer Infos
NCT01937780 Anal Cancer Radiotherapy Study Observational N/A Active but recruitment closed Norway Anal Cancer Infos
NCT01939665 PANFIRE Study: Irreversible Electroporation (IRE) to Treat Locally Advanced Pancreatic Carcinoma Interventional Phase 1/Phase 2 Unknown status Netherlands Pancreatic Cancer Infos
NCT01943786 RAS Switch in Patients With Metastatic RAS Native Colorectal Tumors Treated With 1st Line FOLFIRI-Cetuximab Observational N/A Unknown status Spain Colorectal Cancer Metastatic Infos
NCT01945723 Tissue Characterization From Various Parts of the Gastrointestinal Tract in Healthy Volunteers Observational N/A Unknown status Israel Healthy Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Austria Antimetabolites, Antineoplastic Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Austria Digestive System Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Austria Digestive System Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Austria Endocrine Gland Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Austria Endocrine System Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Austria Gemcitabine Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Austria Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Austria Neoplasms by Site Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Austria Pancreatic Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Austria Pancreatic Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Belgium Antimetabolites, Antineoplastic Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Belgium Digestive System Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Belgium Digestive System Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Belgium Endocrine Gland Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Belgium Endocrine System Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Belgium Gemcitabine Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Belgium Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Belgium Neoplasms by Site Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Belgium Pancreatic Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Belgium Pancreatic Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Czechia Antimetabolites, Antineoplastic Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Czechia Digestive System Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Czechia Digestive System Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Czechia Endocrine Gland Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Czechia Endocrine System Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Czechia Gemcitabine Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Czechia Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Czechia Neoplasms by Site Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Czechia Pancreatic Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Czechia Pancreatic Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Denmark Antimetabolites, Antineoplastic Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Denmark Digestive System Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Denmark Digestive System Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Denmark Endocrine Gland Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Denmark Endocrine System Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Denmark Gemcitabine Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Denmark Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Denmark Neoplasms by Site Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Denmark Pancreatic Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Denmark Pancreatic Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Finland Antimetabolites, Antineoplastic Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Finland Digestive System Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Finland Digestive System Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Finland Endocrine Gland Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Finland Endocrine System Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Finland Gemcitabine Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Finland Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Finland Neoplasms by Site Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Finland Pancreatic Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Finland Pancreatic Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed France Antimetabolites, Antineoplastic Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed France Digestive System Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed France Digestive System Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed France Endocrine Gland Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed France Endocrine System Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed France Gemcitabine Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed France Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed France Neoplasms by Site Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed France Pancreatic Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed France Pancreatic Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Germany Antimetabolites, Antineoplastic Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Germany Digestive System Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Germany Digestive System Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Germany Endocrine Gland Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Germany Endocrine System Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Germany Gemcitabine Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Germany Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Germany Neoplasms by Site Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Germany Pancreatic Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Germany Pancreatic Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Hungary Antimetabolites, Antineoplastic Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Hungary Digestive System Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Hungary Digestive System Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Hungary Endocrine Gland Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Hungary Endocrine System Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Hungary Gemcitabine Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Hungary Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Hungary Neoplasms by Site Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Hungary Pancreatic Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Hungary Pancreatic Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Ireland Antimetabolites, Antineoplastic Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Ireland Digestive System Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Ireland Digestive System Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Ireland Endocrine Gland Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Ireland Endocrine System Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Ireland Gemcitabine Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Ireland Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Ireland Neoplasms by Site Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Ireland Pancreatic Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Ireland Pancreatic Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Italy Antimetabolites, Antineoplastic Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Italy Digestive System Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Italy Digestive System Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Italy Endocrine Gland Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Italy Endocrine System Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Italy Gemcitabine Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Italy Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Italy Neoplasms by Site Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Italy Pancreatic Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Italy Pancreatic Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Netherlands Antimetabolites, Antineoplastic Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Netherlands Digestive System Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Netherlands Digestive System Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Netherlands Endocrine Gland Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Netherlands Endocrine System Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Netherlands Gemcitabine Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Netherlands Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Netherlands Neoplasms by Site Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Netherlands Pancreatic Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Netherlands Pancreatic Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Portugal Antimetabolites, Antineoplastic Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Portugal Digestive System Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Portugal Digestive System Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Portugal Endocrine Gland Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Portugal Endocrine System Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Portugal Gemcitabine Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Portugal Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Portugal Neoplasms by Site Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Portugal Pancreatic Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Portugal Pancreatic Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Spain Antimetabolites, Antineoplastic Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Spain Digestive System Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Spain Digestive System Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Spain Endocrine Gland Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Spain Endocrine System Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Spain Gemcitabine Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Spain Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Spain Neoplasms by Site Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Spain Pancreatic Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed Spain Pancreatic Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed United Kingdom Antimetabolites, Antineoplastic Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed United Kingdom Digestive System Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed United Kingdom Digestive System Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed United Kingdom Endocrine Gland Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed United Kingdom Endocrine System Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed United Kingdom Gemcitabine Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed United Kingdom Neoplasms Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed United Kingdom Neoplasms by Site Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed United Kingdom Pancreatic Diseases Infos
NCT01964430 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Interventional Phase 3 Active but recruitment closed United Kingdom Pancreatic Neoplasms Infos
NCT01964534 Efficacy of ABI-007 Plus Gemcitabine or sLV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer Interventional Phase 2 Unknown status France Metastatic Pancreatic Cancer Infos
NCT01966081 AGARIC Case Control Study Interventional N/A Unknown status France First Recently-diagnosed Colorectal Cancer Infos
NCT01968213 A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Interventional Phase 3 Active but recruitment closed Belgium Peritoneal Cancer Infos
NCT01968213 A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Interventional Phase 3 Active but recruitment closed France Peritoneal Cancer Infos
NCT01968213 A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Interventional Phase 3 Active but recruitment closed Germany Peritoneal Cancer Infos
NCT01968213 A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Interventional Phase 3 Active but recruitment closed Israel Peritoneal Cancer Infos
NCT01968213 A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Interventional Phase 3 Active but recruitment closed Italy Peritoneal Cancer Infos
NCT01968213 A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Interventional Phase 3 Active but recruitment closed Spain Peritoneal Cancer Infos
NCT01968213 A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Interventional Phase 3 Active but recruitment closed United Kingdom Peritoneal Cancer Infos
NCT01983098 Analysis of Circulating Tumor DNA to Monitor Metastatic Colorectal Cancer Treatment Observational N/A Unknown status France To Compare the Monitoring of Circulating Tumor DNA With the Efficacy of Chemotherapy Evaluated by Computer Tomography Scan. Infos
NCT01988493 Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma Interventional Phase 1/Phase 2 Active but recruitment closed Germany Carcinoma, Hepatocellular Infos
NCT01991080 The Relationship Between Relaxation or Wheat Germ Juice to the Immune Indices and Quality of Life (QoL) in Colorectal Cancer Patients on Adjuvant Chemotherapy Interventional N/A Unknown status Israel Colon Cancer Infos
NCT01991873 Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer Interventional Phase 2 Recruitment open Germany Metastatic Colorectal Cancer Infos
NCT01995942 Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer (MARVEL) Trial Observational N/A Active but recruitment closed United Kingdom Digestive System Neoplasms Infos
NCT02002195 Modified Folinic Acid-Fluorouracil-Oxaliplatin Regimen + Capecitabine for Elderly With Metastatic Gastric Cancer Observational N/A Recruitment open Italy Metastatic Gastric Cancer Infos
NCT02002299 Does Surface Tell us About the Invasive Front in Colorectal Cancer Observational N/A Unknown status Denmark Colorectal Cancer Infos
NCT02005965 Low Rectal Cancer Study (MERCURY II) Observational N/A Active but recruitment closed Germany Digestive System Neoplasms Infos
NCT02005965 Low Rectal Cancer Study (MERCURY II) Observational N/A Active but recruitment closed Serbia Digestive System Neoplasms Infos
NCT02005965 Low Rectal Cancer Study (MERCURY II) Observational N/A Active but recruitment closed United Kingdom Digestive System Neoplasms Infos
NCT02007148 MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer Interventional Phase 2 Recruitment open Italy Gastric Adenocarcinoma Infos
NCT02007148 MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer Interventional Phase 2 Recruitment open Italy Gastroesophageal Junction Adenocarcinoma Infos
NCT02012699 Integrated Cancer Repository for Cancer Research Observational N/A Recruitment open Italy Anal Cancer Infos
NCT02012699 Integrated Cancer Repository for Cancer Research Observational N/A Recruitment open Italy Colon Cancer Infos
NCT02012699 Integrated Cancer Repository for Cancer Research Observational N/A Recruitment open Italy Familial Adenomatous Polyposis Infos
NCT02012699 Integrated Cancer Repository for Cancer Research Observational N/A Recruitment open Italy Gastric Cancer Infos
NCT02012699 Integrated Cancer Repository for Cancer Research Observational N/A Recruitment open Italy Liver Cancer Infos
NCT02012699 Integrated Cancer Repository for Cancer Research Observational N/A Recruitment open Italy Lynch Syndrome Infos
NCT02012699 Integrated Cancer Repository for Cancer Research Observational N/A Recruitment open Italy Pancreatic Cancer Infos
NCT02015923 Resection vs no Resection of the Primary in Colorectal Cancer With Unresectable Metastases Interventional Phase 4 Active but recruitment closed Spain Colonic Cancer Infos
NCT02015923 Resection vs no Resection of the Primary in Colorectal Cancer With Unresectable Metastases Interventional Phase 4 Active but recruitment closed Spain Unresectable Metastasis Originating in Colonic Cancer Infos
NCT02024009 Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2 Interventional Phase 1/Phase 2 Recruitment open United Kingdom Pancreatic Neoplasms (Locally Advanced Non-metastatic) Infos
NCT02039336 Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC Interventional Phase 1/Phase 2 Unknown status Netherlands Colorectal Cancer Infos
NCT02045680 RADOX' Reduced Abdominal Distension and Oxygen Delivery Observational N/A Unknown status United Kingdom Colorectal Cancer Infos
NCT02047513 Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer Interventional Phase 2 Active but recruitment closed Germany Ductal Adenocarcinoma of the Pancreas Infos
NCT02047513 Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer Interventional Phase 2 Active but recruitment closed Germany Resectable Pancreatic Cancer Infos
NCT02047994 Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality Interventional Phase 4 Recruitment open Latvia Atrophic Gastritis Infos
NCT02047994 Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality Interventional Phase 4 Recruitment open Latvia Gastric Cancer Infos
NCT02047994 Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality Interventional Phase 4 Recruitment open Latvia Helicobacter Pylori Infections Infos
NCT02050737 Plasma Biomarkers C-RAC, ICORG 12-27, V1 Observational N/A Active but recruitment closed Ireland Colorectal Cancer Infos
NCT02051283 Pretreatment MRI Predicting Outcome After Radio-frequency Ablation of HCC Observational N/A Unknown status Belgium Hepatocellular Carcinoma Infos
NCT02051868 International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel Interventional Phase 2 Unknown status United Kingdom Squamous Cell Carcinoma of the Anus Infos
NCT02053805 Prostate Cancer Screening Among Men With High Risk Genetic Predisposition Interventional N/A Unknown status Israel Lynch Syndrome Infos
NCT02060188 An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread Interventional Phase 2 Active but recruitment closed Belgium Microsatellite Stable Colorectal Cancer Infos
NCT02060188 An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread Interventional Phase 2 Active but recruitment closed Belgium Microsatellite Unstable Colorectal Cancer Infos
NCT02060188 An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread Interventional Phase 2 Active but recruitment closed Belgium Mismatch Repair Deficient Colorectal Cancer Infos
NCT02060188 An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread Interventional Phase 2 Active but recruitment closed Belgium Mismatch Repair Proficient Colorectal Cancer Infos
NCT02060188 An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread Interventional Phase 2 Active but recruitment closed France Microsatellite Stable Colorectal Cancer Infos
NCT02060188 An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread Interventional Phase 2 Active but recruitment closed France Microsatellite Unstable Colorectal Cancer Infos
NCT02060188 An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread Interventional Phase 2 Active but recruitment closed France Mismatch Repair Deficient Colorectal Cancer Infos
NCT02060188 An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread Interventional Phase 2 Active but recruitment closed France Mismatch Repair Proficient Colorectal Cancer Infos
NCT02060188 An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread Interventional Phase 2 Active but recruitment closed Ireland Microsatellite Stable Colorectal Cancer Infos
NCT02060188 An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread Interventional Phase 2 Active but recruitment closed Ireland Microsatellite Unstable Colorectal Cancer Infos
NCT02060188 An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread Interventional Phase 2 Active but recruitment closed Ireland Mismatch Repair Deficient Colorectal Cancer Infos
NCT02060188 An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread Interventional Phase 2 Active but recruitment closed Ireland Mismatch Repair Proficient Colorectal Cancer Infos
NCT02060188 An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread Interventional Phase 2 Active but recruitment closed Italy Microsatellite Stable Colorectal Cancer Infos
NCT02060188 An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread Interventional Phase 2 Active but recruitment closed Italy Microsatellite Unstable Colorectal Cancer Infos
NCT02060188 An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread Interventional Phase 2 Active but recruitment closed Italy Mismatch Repair Deficient Colorectal Cancer Infos
NCT02060188 An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread Interventional Phase 2 Active but recruitment closed Italy Mismatch Repair Proficient Colorectal Cancer Infos
NCT02060188 An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread Interventional Phase 2 Active but recruitment closed Spain Microsatellite Stable Colorectal Cancer Infos
NCT02060188 An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread Interventional Phase 2 Active but recruitment closed Spain Microsatellite Unstable Colorectal Cancer Infos
NCT02060188 An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread Interventional Phase 2 Active but recruitment closed Spain Mismatch Repair Deficient Colorectal Cancer Infos
NCT02060188 An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread Interventional Phase 2 Active but recruitment closed Spain Mismatch Repair Proficient Colorectal Cancer Infos
NCT02066259 OctavaColon Cancer Blood Tests OctavaGold and OctavaSilver - Blood Tests for the Help in Diagnosis of Colon Cancer Clinical Study Protocol Observational N/A Unknown status Israel Colon Cancer Infos
NCT02070146 Prospective Data Collection Initiative on Colorectal Cancer Observational N/A Recruitment open Netherlands Colorectal Cancer Infos
NCT02075086 Angiogenic Switch in Patients With Colorectal Cancer Interventional Phase 2 Unknown status Spain Colorectal Cancer Infos
NCT02077868 Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment Interventional Phase 3 Active but recruitment closed Austria Metastatic Colorectal Cancer Infos
NCT02077868 Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment Interventional Phase 3 Active but recruitment closed Belgium Metastatic Colorectal Cancer Infos
NCT02077868 Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment Interventional Phase 3 Active but recruitment closed Estonia Metastatic Colorectal Cancer Infos
NCT02077868 Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment Interventional Phase 3 Active but recruitment closed France Metastatic Colorectal Cancer Infos
NCT02077868 Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment Interventional Phase 3 Active but recruitment closed Germany Metastatic Colorectal Cancer Infos
NCT02077868 Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment Interventional Phase 3 Active but recruitment closed Italy Metastatic Colorectal Cancer Infos
NCT02077868 Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment Interventional Phase 3 Active but recruitment closed Spain Metastatic Colorectal Cancer Infos
NCT02077868 Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment Interventional Phase 3 Active but recruitment closed United Kingdom Metastatic Colorectal Cancer Infos
NCT02078245 Quality Control Study of MR Based Screening of Individual With Increased Risk for Pancreas Cancer. Observational N/A Recruitment open Sweden Hereditary Pancreatic Cancer Infos
NCT02078245 Quality Control Study of MR Based Screening of Individual With Increased Risk for Pancreas Cancer. Observational N/A Recruitment open Sweden Hereditary Pancreatitis Infos
NCT02079363 DNA Promoter Hypermethylation as a Blood Based Maker for Pancreatic Cancer Observational N/A Unknown status Denmark Pancreatic Diseases Infos
NCT02079363 DNA Promoter Hypermethylation as a Blood Based Maker for Pancreatic Cancer Observational N/A Unknown status Denmark Pancreatic Neoplasms Infos
NCT02079363 DNA Promoter Hypermethylation as a Blood Based Maker for Pancreatic Cancer Observational N/A Unknown status Denmark Pancreatitis Infos
NCT02089269 Tumor Registry Pancreatic Cancer Observational N/A Recruitment open Germany Pancreas Cancer Infos
NCT02112357 Feasibility of a Molecular Characterisation Approach to Treatment Observational N/A Unknown status United Kingdom Advanced Gastrointestinal Cancers Infos
NCT02117466 Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer Interventional Phase 1/Phase 2 Recruitment open Netherlands Metastatic Colorectal Cancer Infos
NCT02125136 Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer Interventional Phase 2 Active but recruitment closed Germany Ductal Adenocarcinoma of the Pancreas Infos
NCT02125409 Acetylsalicylic Acid and Colorectal Cancer Prevention: Exploring the Platelet Function of Its Mechanism of Action Interventional Phase 3 Unknown status Spain Colorectal Cancer Infos
NCT02128243 Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer Interventional Phase 2 Active but recruitment closed Germany Esophageal Adenocarcinoma Infos
NCT02128243 Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer Interventional Phase 2 Active but recruitment closed Germany Esophageal Neoplasms Infos
NCT02128243 Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer Interventional Phase 2 Active but recruitment closed Germany Gastric Adenocarcinoma Infos
NCT02128243 Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer Interventional Phase 2 Active but recruitment closed Germany Gastric Neoplasm Infos
NCT02128243 Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer Interventional Phase 2 Active but recruitment closed Germany Gastroesophageal Junction Adenocarcinoma Infos
NCT02128243 Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer Interventional Phase 2 Active but recruitment closed Germany Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction Infos
NCT02128958 Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) Interventional Phase 2 Active but recruitment closed Bulgaria Hepatocellular Carcinoma Infos
NCT02128958 Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) Interventional Phase 2 Active but recruitment closed Israel Hepatocellular Carcinoma Infos
NCT02128958 Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) Interventional Phase 2 Active but recruitment closed Romania Hepatocellular Carcinoma Infos
NCT02128958 Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) Interventional Phase 2 Active but recruitment closed Serbia Hepatocellular Carcinoma Infos
NCT02138370 Comprehensive Immune-landscape in Localized Colorectal Cancer Observational N/A Unknown status Switzerland Colorectal Cancer Infos
NCT02138370 Comprehensive Immune-landscape in Localized Colorectal Cancer Observational N/A Unknown status Switzerland Immune Landscape Infos
NCT02143219 Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer Interventional Phase 2 Active but recruitment closed France Pancreatic Metastatic Cancer Infos
NCT02143219 Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer Interventional Phase 2 Active but recruitment closed France Toxicity Infos
NCT02145013 Portal Hypertension and Liver Resection in Patients With Hepatocellular Carcinoma Observational N/A Unknown status France Primary Liver Cancers Infos
NCT02158988 Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis Interventional Phase 3 Active but recruitment closed Germany Malignant Neoplasm of Stomach Infos
NCT02158988 Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis Interventional Phase 3 Active but recruitment closed Germany Secondary Malignant Neoplasm of Other and Unspecified Sites Infos
NCT02158988 Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis Interventional Phase 3 Active but recruitment closed Germany Secondary Malignant Neoplasm of Peritoneum Infos
NCT02162563 Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases Interventional Phase 3 Recruitment open Belgium Colorectal Cancer Infos
NCT02162563 Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases Interventional Phase 3 Recruitment open Belgium Liver Metastases Infos
NCT02162563 Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases Interventional Phase 3 Recruitment open Netherlands Colorectal Cancer Infos
NCT02162563 Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases Interventional Phase 3 Recruitment open Netherlands Liver Metastases Infos
NCT02164149 Length of Tumour Feeding Artery After Colon Cancer Surgery Observational N/A Unknown status Denmark Colon Cancer Infos
NCT02173990 Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US (PULSAR). Interventional Phase 2 Unknown status France Metastatic Colorectal Cancer Infos
NCT02175914 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Interventional Phase 4 Unknown status Israel FAP-Familial Adenomatous Polyposis Infos
NCT02184195 Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy Interventional Phase 3 Active but recruitment closed Belgium Germline BRCA1/2 Mutations and Infos
NCT02184195 Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy Interventional Phase 3 Active but recruitment closed Belgium Metastatic Adenocarcinoma of the Pancreas Infos
NCT02184195 Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy Interventional Phase 3 Active but recruitment closed France Germline BRCA1/2 Mutations and Infos
NCT02184195 Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy Interventional Phase 3 Active but recruitment closed France Metastatic Adenocarcinoma of the Pancreas Infos
NCT02184195 Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy Interventional Phase 3 Active but recruitment closed Germany Germline BRCA1/2 Mutations and Infos
NCT02184195 Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy Interventional Phase 3 Active but recruitment closed Germany Metastatic Adenocarcinoma of the Pancreas Infos
NCT02184195 Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy Interventional Phase 3 Active but recruitment closed Israel Germline BRCA1/2 Mutations and Infos
NCT02184195 Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy Interventional Phase 3 Active but recruitment closed Israel Metastatic Adenocarcinoma of the Pancreas Infos
NCT02184195 Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy Interventional Phase 3 Active but recruitment closed Italy Germline BRCA1/2 Mutations and Infos
NCT02184195 Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy Interventional Phase 3 Active but recruitment closed Italy Metastatic Adenocarcinoma of the Pancreas Infos
NCT02184195 Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy Interventional Phase 3 Active but recruitment closed Netherlands Germline BRCA1/2 Mutations and Infos
NCT02184195 Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy Interventional Phase 3 Active but recruitment closed Netherlands Metastatic Adenocarcinoma of the Pancreas Infos
NCT02184195 Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy Interventional Phase 3 Active but recruitment closed Spain Germline BRCA1/2 Mutations and Infos
NCT02184195 Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy Interventional Phase 3 Active but recruitment closed Spain Metastatic Adenocarcinoma of the Pancreas Infos
NCT02184195 Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy Interventional Phase 3 Active but recruitment closed United Kingdom Germline BRCA1/2 Mutations and Infos
NCT02184195 Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy Interventional Phase 3 Active but recruitment closed United Kingdom Metastatic Adenocarcinoma of the Pancreas Infos
NCT02184663 Evaluation of an Adapted Physical Activity Program in Patients With Unresectable Pancreatic Cancer Interventional N/A Recruitment open France Metastatic Pancreatic Cancer Infos
NCT02184663 Evaluation of an Adapted Physical Activity Program in Patients With Unresectable Pancreatic Cancer Interventional N/A Recruitment open France Unresectable Locally Advanced Cancer Infos
NCT02188927 Effect of an Advanced Notification Letter on Screening Colonoscopy Participation Interventional N/A Unknown status Poland Colorectal Cancer Infos
NCT02197351 Narrow Band Imaging for Gastric Neoplasia Interventional N/A Recruitment open Portugal Gastric Cancer Infos
NCT02208804 Surefire Infusion System vs. Standard Microcatheter Use During Holmium-166 Radioembolization Interventional Phase 2/Phase 3 Unknown status Netherlands Digestive System Neoplasms Infos
NCT02209415 EUFURO - EUS-based Follow-Up on R0-resected Patients for Esophageal, Gastric and Pancreatic Cancer Interventional N/A Unknown status Denmark Esophageal Cancer Infos
NCT02209415 EUFURO - EUS-based Follow-Up on R0-resected Patients for Esophageal, Gastric and Pancreatic Cancer Interventional N/A Unknown status Denmark Pancreatic Cancer Infos
NCT02209415 EUFURO - EUS-based Follow-Up on R0-resected Patients for Esophageal, Gastric and Pancreatic Cancer Interventional N/A Unknown status Denmark Stomach Cancer Infos
NCT02215577 ALPPS Versus PVE/PL Interventional N/A Unknown status Denmark Colorectal Cancer Infos
NCT02215577 ALPPS Versus PVE/PL Interventional N/A Unknown status Norway Colorectal Cancer Infos
NCT02215577 ALPPS Versus PVE/PL Interventional N/A Unknown status Sweden Colorectal Cancer Infos
NCT02215889 Partial Liver Segment 2/3 Transplantation Study Interventional Phase 1/Phase 2 Recruitment open Norway Colorectal Cancer Infos
NCT02216578 Ph II CABOGIST in GIST Interventional Phase 2 Active but recruitment closed Belgium Metastatic Gastrointestinal Stromal Tumor Infos
NCT02216578 Ph II CABOGIST in GIST Interventional Phase 2 Active but recruitment closed Czechia Metastatic Gastrointestinal Stromal Tumor Infos
NCT02216578 Ph II CABOGIST in GIST Interventional Phase 2 Active but recruitment closed France Metastatic Gastrointestinal Stromal Tumor Infos
NCT02216578 Ph II CABOGIST in GIST Interventional Phase 2 Active but recruitment closed Germany Metastatic Gastrointestinal Stromal Tumor Infos
NCT02216578 Ph II CABOGIST in GIST Interventional Phase 2 Active but recruitment closed Hungary Metastatic Gastrointestinal Stromal Tumor Infos
NCT02216578 Ph II CABOGIST in GIST Interventional Phase 2 Active but recruitment closed United Kingdom Metastatic Gastrointestinal Stromal Tumor Infos
NCT02230553 Lapatinib Plus Trametinib in KRAS Mutant NSCLC Interventional Phase 1/Phase 2 Unknown status Netherlands Colorectal Cancer Infos
NCT02231086 Adjuvant HIPEC in High Risk Colon Cancer Interventional Phase 3 Active but recruitment closed Netherlands Colorectal Neoplasms Infos
NCT02231086 Adjuvant HIPEC in High Risk Colon Cancer Interventional Phase 3 Active but recruitment closed Netherlands Peritoneal Neoplasms Infos
NCT02231385 Acetic Acid Colonoscopy Enhancement Study Interventional N/A Unknown status Italy Colorectal Cancer Infos
NCT02246322 A Clinical Trial With a New Needle Device Comparing Two Needles for EUS_FNA of Solid Lesions. Interventional N/A Unknown status Italy Pancreatic Cancer Infos
NCT02246634 Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE) Interventional N/A Unknown status United Kingdom Colorectal Neoplasms Infos
NCT02246634 Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE) Interventional N/A Unknown status United Kingdom Hepatic Neoplasms Infos
NCT02246634 Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE) Interventional N/A Unknown status United Kingdom Neoplasm Metastases Infos
NCT02246725 Observational Study of Early Contact With Palliative Care Unit for Patients Receiving First Line Palliative Chemotherapy With Cancer in Upper Gastrointestinal Canal, or Second Line Palliative Chemotherapy in Patients With Colorectal Cancer - an Open, Randomised Investigator Initiated Trial. Observational N/A Recruitment open Sweden Tumor in Upper Gastrointestinal Canal or Patients With Colorectal Cancer Infos
NCT02248519 Laparoscopic Versus Open Gastrectomy for Gastric Cancer Interventional N/A Active but recruitment closed Netherlands Gastric Cancer Infos
NCT02254941 Observational Study to Evaluate the Use of Targeted Therapies in Metastatic Colorectal Cancer Observational N/A Active but recruitment closed Spain Metastatic Colon Cancer Infos
NCT02260128 Effect of Chewing Gum on Postoperative Bowel Function Following Upper GI Tract Cancer Surgery Interventional N/A Unknown status Denmark Pancreatic Cancer Infos
NCT02260505 Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) Interventional Phase 3 Recruitment open France Gastrointestinal Stromal Tumors Infos
NCT02260505 Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) Interventional Phase 3 Recruitment open France Resected Gastrointestinal Stromal Tumors Infos
NCT02272790 Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Interventional Phase 2 Active but recruitment closed Netherlands Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation Infos
NCT02272790 Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Interventional Phase 2 Active but recruitment closed United Kingdom Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation Infos
NCT02274753 Personalizing Colorectal Cancer Medicine (ImmuCol2) Observational N/A Unknown status France Colon Cancer Infos
NCT02291289 A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) Interventional Phase 2 Active but recruitment closed Belgium Colorectal Cancer Infos
NCT02291289 A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) Interventional Phase 2 Active but recruitment closed Bosnia and Herzegovina Colorectal Cancer Infos
NCT02291289 A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) Interventional Phase 2 Active but recruitment closed Cyprus Colorectal Cancer Infos
NCT02291289 A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) Interventional Phase 2 Active but recruitment closed Denmark Colorectal Cancer Infos
NCT02291289 A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) Interventional Phase 2 Active but recruitment closed France Colorectal Cancer Infos
NCT02291289 A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) Interventional Phase 2 Active but recruitment closed Germany Colorectal Cancer Infos
NCT02291289 A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) Interventional Phase 2 Active but recruitment closed Greece Colorectal Cancer Infos
NCT02291289 A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) Interventional Phase 2 Active but recruitment closed Italy Colorectal Cancer Infos
NCT02291289 A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) Interventional Phase 2 Active but recruitment closed Netherlands Colorectal Cancer Infos
NCT02291289 A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) Interventional Phase 2 Active but recruitment closed Poland Colorectal Cancer Infos
NCT02291289 A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) Interventional Phase 2 Active but recruitment closed Portugal Colorectal Cancer Infos
NCT02291289 A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) Interventional Phase 2 Active but recruitment closed Russian Federation Colorectal Cancer Infos
NCT02291289 A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) Interventional Phase 2 Active but recruitment closed Serbia Colorectal Cancer Infos
NCT02291289 A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) Interventional Phase 2 Active but recruitment closed Slovakia Colorectal Cancer Infos
NCT02291289 A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) Interventional Phase 2 Active but recruitment closed Slovenia Colorectal Cancer Infos
NCT02291289 A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) Interventional Phase 2 Active but recruitment closed Spain Colorectal Cancer Infos
NCT02291289 A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) Interventional Phase 2 Active but recruitment closed Sweden Colorectal Cancer Infos
NCT02291289 A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) Interventional Phase 2 Active but recruitment closed Turkey Colorectal Cancer Infos
NCT02291289 A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) Interventional Phase 2 Active but recruitment closed United Kingdom Colorectal Cancer Infos
NCT02296203 Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET). Interventional Phase 2 Unknown status Italy Metastatic Colorectal Cancer Infos
NCT02299596 Physical Activity in Relation to Surgical Procedures Interventional N/A Active but recruitment closed Sweden Colorectal Cancer Infos
NCT02300922 Pretargeted Radioimmunotherapy in Metastatic Colorectal Cancer Interventional Phase 1/Phase 2 Unknown status France Metastatic Colorectal Cancer Infos
NCT02301286 A Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients Interventional Phase 3 Recruitment open Netherlands Adjuvant Therapy Infos
NCT02301286 A Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients Interventional Phase 3 Recruitment open Netherlands Colon Cancer Infos
NCT02304978 Prognostic Value of Tissue Factor (TF) in Blood t in Colorectal Cancer in Adults Interventional Early Phase 1 Recruitment open France Colorectal Cancer Infos
NCT02307500 Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy Interventional Phase 2 Active but recruitment closed Italy Pancreas Cancer Infos
NCT02308722 SBRT Pre-operatively for Pancreatic Cancer Interventional Phase 1 Unknown status United Kingdom Pancreatic Neoplasms Infos
NCT02323464 Prevalence of Sleep Apnea in Patients Undergoing Surgery for Colorectal Cancer Observational N/A Recruitment open Sweden Colorectal Cancer Infos
NCT02323464 Prevalence of Sleep Apnea in Patients Undergoing Surgery for Colorectal Cancer Observational N/A Recruitment open Sweden Hypoxemia Infos
NCT02323464 Prevalence of Sleep Apnea in Patients Undergoing Surgery for Colorectal Cancer Observational N/A Recruitment open Sweden Sleep Apnea Syndromes Infos
NCT02325323 Prognosis and Risk Factors of Gastric Cancer in Patients With Intestinal Metaplasia Observational N/A Unknown status France Stomach Cancer Infos
NCT02325453 Robotic, Laparoscopic and Open Surgery for Gastric Cancer Compared on Surgical, Clinical and Oncological Outcomes Observational N/A Recruitment open Italy Gastric Cancer Infos
NCT02327494 Study to Evaluate Oxygen Monitoring at Different Stages of Neuromuscular Blockade in Colorectal Surgery Observational N/A Unknown status Spain Colorectal Cancer Infos
NCT02327819 The Effect of Branched-chain Amino Acid (BCAA) on the Progression of Primary Liver Cancer Interventional N/A Unknown status Israel Primary Liver Cancer Infos
NCT02328677 ColoCare Study - Colorectal Cancer Cohort Observational N/A Recruitment open Germany Colorectal Cancer Infos
NCT02331927 PERMAD: Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer Interventional Phase 2 Active but recruitment closed Germany Metastatic Colorectal Cancer Infos
NCT02339116 Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC Interventional Phase 3 Active but recruitment closed Italy Metastatic Colorectal Cancer Infos
NCT02345408 Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma Interventional Phase 1 Active but recruitment closed Netherlands Pancreatic Cancer Infos
NCT02347735 Predictive Factors for Anastomotic Leakage After Colorectal Surgery Observational N/A Unknown status Netherlands Colorectal Cancer Infos
NCT02352337 First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem Interventional Phase 2 Active but recruitment closed France Metastatic Pancreatic Cancer Infos
NCT02355119 Italian Multicenter Study Comparing FOLFOXIRI Versus Gemcitabine as Adjuvant Treatment for Resected Pancreatic Cancer Interventional Phase 3 Unknown status Italy Pancreatic Cancer Infos
NCT02356406 Celiac Plexus Radiosurgery for Pain Management Interventional Phase 2 Unknown status Israel Digestive System Neoplasms Infos
NCT02363049 Colectomy in Patients With Asymptomatic and Unresectable Stage IV Colon Cancer Interventional Phase 3 Unknown status France Colon Cancer Liver Metastasis Infos
NCT02363049 Colectomy in Patients With Asymptomatic and Unresectable Stage IV Colon Cancer Interventional Phase 3 Unknown status France Malignant Neoplasm of Large Intestine Infos
NCT02372500 Trial of Chewing Gum to Reduce Post Operative Ileus in Elective Colorectal Surgery Interventional N/A Unknown status United Kingdom Colorectal Cancer Infos
NCT02379039 Multimodal Monitoring of Radiotherapy Response in Squamous Cell Cancer Observational N/A Recruitment open Sweden Anal Cancer Infos
NCT02384759 Aflibercept +/- LV5FU2 in First Line of Non-resectalbe Metastatic Colorectal Cancers Interventional Phase 2 Recruitment open France Colorectal Neoplasms Infos
NCT02393248 Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) Interventional Phase 1/Phase 2 Recruitment open Denmark Gastric Cancer Infos
NCT02395224 A Longitudinal Study of Colorectal Cancer Patients With Metastatic Disease in Middle-Norway Observational N/A Recruitment open Norway Neoplasm Metastasis Infos
NCT02395224 A Longitudinal Study of Colorectal Cancer Patients With Metastatic Disease in Middle-Norway Observational N/A Recruitment open Norway Neoplasms, Colorectal Infos
NCT02403050 Feasibility Study of Fiducial Markers in Oesophageal Cancer Observational N/A Unknown status United Kingdom Esophageal Neoplasms Infos
NCT02404935 Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC) Interventional Phase 2 Active but recruitment closed France Metastatic Colorectal Cancer Infos
NCT02414009 Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients Interventional Phase 2 Unknown status Italy Metastatic Colorectal Cancer Infos
NCT02416609 Low-dose Radiotherapy Plus Chemotherapy With GemOx and Stereotactic Radiotherapy for Advanced Pancreatic Cancer Interventional N/A Recruitment open Italy Pancreatic Cancer Infos
NCT02423239 A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours Interventional Phase 1 Unknown status Germany Hepatocellular Carcinoma Infos
NCT02423239 A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours Interventional Phase 1 Unknown status Germany Pancreatic Cancer Infos
NCT02423239 A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours Interventional Phase 1 Unknown status Poland Hepatocellular Carcinoma Infos
NCT02423239 A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours Interventional Phase 1 Unknown status Poland Pancreatic Cancer Infos
NCT02423239 A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours Interventional Phase 1 Unknown status Spain Hepatocellular Carcinoma Infos
NCT02423239 A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours Interventional Phase 1 Unknown status Spain Pancreatic Cancer Infos
NCT02423239 A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours Interventional Phase 1 Unknown status United Kingdom Hepatocellular Carcinoma Infos
NCT02423239 A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours Interventional Phase 1 Unknown status United Kingdom Pancreatic Cancer Infos
NCT02423785 Ocular Blood Flow in Colorectal Cancer Patients Observational N/A Recruitment open Austria Metastatic Colorectal Cancer Infos
NCT02424279 Invasive Treatment of Pain Associated With Pancreatic Cancer on Different Levels of WHO Analgesic Ladder Interventional N/A Unknown status Poland Pain Infos
NCT02424279 Invasive Treatment of Pain Associated With Pancreatic Cancer on Different Levels of WHO Analgesic Ladder Interventional N/A Unknown status Poland Pancreatic Cancer Infos
NCT02425657 Fast Track Module Based Colonoscopy Training Programme for Surgical Trainees at North Jutland Surgical Departments Observational N/A Recruitment open Denmark Colorectal Cancer Infos
NCT02435433 A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein Interventional Phase 3 Recruitment open Austria Hepatocellular Carcinoma Infos
NCT02435433 A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein Interventional Phase 3 Recruitment open Belgium Hepatocellular Carcinoma Infos
NCT02435433 A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein Interventional Phase 3 Recruitment open Czechia Hepatocellular Carcinoma Infos
NCT02435433 A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein Interventional Phase 3 Recruitment open France Hepatocellular Carcinoma Infos
NCT02435433 A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein Interventional Phase 3 Recruitment open Germany Hepatocellular Carcinoma Infos
NCT02435433 A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein Interventional Phase 3 Recruitment open Israel Hepatocellular Carcinoma Infos
NCT02435433 A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein Interventional Phase 3 Recruitment open Italy Hepatocellular Carcinoma Infos
NCT02435433 A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein Interventional Phase 3 Recruitment open Poland Hepatocellular Carcinoma Infos
NCT02435433 A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein Interventional Phase 3 Recruitment open Spain Hepatocellular Carcinoma Infos
NCT02435433 A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein Interventional Phase 3 Recruitment open Switzerland Hepatocellular Carcinoma Infos
NCT02435433 A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein Interventional Phase 3 Recruitment open United Kingdom Hepatocellular Carcinoma Infos
NCT02436564 In Vitro Models of Liver and Pancreatic Cancer Observational N/A Unknown status United Kingdom Cholangiocarcinoma Infos
NCT02436564 In Vitro Models of Liver and Pancreatic Cancer Observational N/A Unknown status United Kingdom Hepatocellular Carcinoma Infos
NCT02436564 In Vitro Models of Liver and Pancreatic Cancer Observational N/A Unknown status United Kingdom Pancreatic Neoplasm Infos
NCT02443948 Circulating Cell-free Tumor DNA in the Plasma of Patients With Gastrointestinal Stromal Tumors (GIST) Observational N/A Unknown status Italy Gastrointestinal Stromal Tumor (GIST) Infos
NCT02456285 Colorectal Cancer With Liver-limited Synchronous Metastases: an Inception Cohort Study of Standardised Care Pathways Observational N/A Active but recruitment closed United Kingdom Colorectal Neoplasms Infos
NCT02456285 Colorectal Cancer With Liver-limited Synchronous Metastases: an Inception Cohort Study of Standardised Care Pathways Observational N/A Active but recruitment closed United Kingdom Liver Neoplasms Infos
NCT02456285 Colorectal Cancer With Liver-limited Synchronous Metastases: an Inception Cohort Study of Standardised Care Pathways Observational N/A Active but recruitment closed United Kingdom Neoplasm Metastasis Infos
NCT02457156 Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy Interventional Phase 3 Unknown status United Kingdom Pancreatic Cancer Infos
NCT02458664 BASE HSP110 : A New Therapeutic Target and a New Marker for Prognosis of Type MSI Colorectal Cancer Observational N/A Unknown status France Cancer of Colon Infos
NCT02458664 BASE HSP110 : A New Therapeutic Target and a New Marker for Prognosis of Type MSI Colorectal Cancer Observational N/A Unknown status France Rectum Cancer Infos
NCT02460198 Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164) Interventional Phase 2 Active but recruitment closed Belgium Colorectal Carcinoma Infos
NCT02460198 Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164) Interventional Phase 2 Active but recruitment closed France Colorectal Carcinoma Infos
NCT02460198 Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164) Interventional Phase 2 Active but recruitment closed Germany Colorectal Carcinoma Infos
NCT02460198 Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164) Interventional Phase 2 Active but recruitment closed Israel Colorectal Carcinoma Infos
NCT02460198 Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164) Interventional Phase 2 Active but recruitment closed Spain Colorectal Carcinoma Infos
NCT02467582 Adjuvant Aspirin Treatment for Colon Cancer Patients Interventional Phase 3 Recruitment open Belgium Colon Cancer Infos
NCT02467582 Adjuvant Aspirin Treatment for Colon Cancer Patients Interventional Phase 3 Recruitment open Germany Colon Cancer Infos
NCT02467582 Adjuvant Aspirin Treatment for Colon Cancer Patients Interventional Phase 3 Recruitment open Hungary Colon Cancer Infos
NCT02467582 Adjuvant Aspirin Treatment for Colon Cancer Patients Interventional Phase 3 Recruitment open Switzerland Colon Cancer Infos
NCT02469480 Intravenous Ferric Carboxymaltose vs. Oral Iron Substitution in Patients With Metastatic Colorectal Cancer (CRC) and Iron Deficiency Anemia: a Randomized Multicenter Treatment Optimization Study. Interventional Phase 2 Active but recruitment closed Germany Metastatic Colorectal Cancer Infos
NCT02470533 Transarterial Chemoembolization Versus Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Interventional Phase 2 Unknown status Belgium Liver Neoplasms Infos
NCT02470533 Transarterial Chemoembolization Versus Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Interventional Phase 2 Unknown status France Liver Neoplasms Infos
NCT02470533 Transarterial Chemoembolization Versus Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Interventional Phase 2 Unknown status Netherlands Liver Neoplasms Infos
NCT02470533 Transarterial Chemoembolization Versus Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Interventional Phase 2 Unknown status Switzerland Liver Neoplasms Infos
NCT02470585 Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Denmark Ovarian Cancer Infos
NCT02470585 Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Denmark Ovarian Neoplasm Infos
NCT02470585 Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Israel Ovarian Cancer Infos
NCT02470585 Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Israel Ovarian Neoplasm Infos
NCT02470585 Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Poland Ovarian Cancer Infos
NCT02470585 Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Poland Ovarian Neoplasm Infos
NCT02470585 Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Spain Ovarian Cancer Infos
NCT02470585 Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Interventional Phase 3 Active but recruitment closed Spain Ovarian Neoplasm Infos
NCT02470585 Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Interventional Phase 3 Active but recruitment closed United Kingdom Ovarian Cancer Infos
NCT02470585 Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Interventional Phase 3 Active but recruitment closed United Kingdom Ovarian Neoplasm Infos
NCT02476045 Panitumumab-based Maintenance in Patients With RAS Wild-type, Metastatic Colorectal Cancer (Valentino) Interventional Phase 2 Unknown status Italy Metastatic Colorectal Cancer Infos
NCT02489058 A Study of Long-Term Responders on Olaparib Observational N/A Recruitment open Italy Peritoneal Cancer Infos
NCT02489058 A Study of Long-Term Responders on Olaparib Observational N/A Recruitment open Spain Peritoneal Cancer Infos
NCT02489058 A Study of Long-Term Responders on Olaparib Observational N/A Recruitment open United Kingdom Peritoneal Cancer Infos
NCT02494973 Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases Interventional Phase 2/Phase 3 Recruitment open France Colorectal Cancer Infos
NCT02497820 Finding the Best Dose of Aspirin to Prevent Lynch Syndrome Cancers Interventional Phase 3 Not yet recruiting Israel Lynch Syndrome I (Site-specific Colonic Cancer) Infos
NCT02502656 RAS Mutation Testing in the Circulating Blood of Patients With Metastatic Colorectal Cancer Observational N/A Unknown status France Colorectal Cancer Infos
NCT02508467 A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma Interventional Phase 1 Active but recruitment closed France Hepatocellular Carcinoma (HCC) Infos
NCT02508467 A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma Interventional Phase 1 Active but recruitment closed Germany Hepatocellular Carcinoma (HCC) Infos
NCT02508467 A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma Interventional Phase 1 Active but recruitment closed Italy Hepatocellular Carcinoma (HCC) Infos
NCT02508467 A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma Interventional Phase 1 Active but recruitment closed Spain Hepatocellular Carcinoma (HCC) Infos
NCT02508467 A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma Interventional Phase 1 Active but recruitment closed Switzerland Hepatocellular Carcinoma (HCC) Infos
NCT02508467 A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma Interventional Phase 1 Active but recruitment closed United Kingdom Hepatocellular Carcinoma (HCC) Infos
NCT02508532 (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors Interventional Phase 1 Active but recruitment closed Belgium Gastrointestinal Stromal Tumors (GIST) Infos
NCT02508532 (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors Interventional Phase 1 Active but recruitment closed Belgium Other Relapsed or Refractory Solid Tumors Infos
NCT02508532 (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors Interventional Phase 1 Active but recruitment closed France Gastrointestinal Stromal Tumors (GIST) Infos
NCT02508532 (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors Interventional Phase 1 Active but recruitment closed France Other Relapsed or Refractory Solid Tumors Infos
NCT02508532 (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors Interventional Phase 1 Active but recruitment closed Germany Gastrointestinal Stromal Tumors (GIST) Infos
NCT02508532 (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors Interventional Phase 1 Active but recruitment closed Germany Other Relapsed or Refractory Solid Tumors Infos
NCT02508532 (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors Interventional Phase 1 Active but recruitment closed Italy Gastrointestinal Stromal Tumors (GIST) Infos
NCT02508532 (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors Interventional Phase 1 Active but recruitment closed Italy Other Relapsed or Refractory Solid Tumors Infos
NCT02508532 (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors Interventional Phase 1 Active but recruitment closed Netherlands Gastrointestinal Stromal Tumors (GIST) Infos
NCT02508532 (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors Interventional Phase 1 Active but recruitment closed Netherlands Other Relapsed or Refractory Solid Tumors Infos
NCT02508532 (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors Interventional Phase 1 Active but recruitment closed Poland Gastrointestinal Stromal Tumors (GIST) Infos
NCT02508532 (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors Interventional Phase 1 Active but recruitment closed Poland Other Relapsed or Refractory Solid Tumors Infos
NCT02508532 (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors Interventional Phase 1 Active but recruitment closed Spain Gastrointestinal Stromal Tumors (GIST) Infos
NCT02508532 (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors Interventional Phase 1 Active but recruitment closed Spain Other Relapsed or Refractory Solid Tumors Infos
NCT02508532 (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors Interventional Phase 1 Active but recruitment closed United Kingdom Gastrointestinal Stromal Tumors (GIST) Infos
NCT02508532 (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors Interventional Phase 1 Active but recruitment closed United Kingdom Other Relapsed or Refractory Solid Tumors Infos
NCT02509507 Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611 Interventional Phase 1 Recruitment open Austria Hepatocellular Carcinoma Infos
NCT02509507 Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611 Interventional Phase 1 Recruitment open Belgium Hepatocellular Carcinoma Infos
NCT02509507 Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611 Interventional Phase 1 Recruitment open Germany Hepatocellular Carcinoma Infos
NCT02509507 Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611 Interventional Phase 1 Recruitment open Poland Hepatocellular Carcinoma Infos
NCT02509507 Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611 Interventional Phase 1 Recruitment open Spain Hepatocellular Carcinoma Infos
NCT02509507 Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611 Interventional Phase 1 Recruitment open Switzerland Hepatocellular Carcinoma Infos
NCT02510001 MEK and MET Inhibition in Colorectal Cancer Interventional Phase 1 Active but recruitment closed United Kingdom Colorectal Cancer Infos
NCT02510001 MEK and MET Inhibition in Colorectal Cancer Interventional Phase 1 Active but recruitment closed United Kingdom Solid Tumor Infos
NCT02511223 Efficacy and Safety of PARPi to Treat Pancreatic Cancer Interventional Phase 2 Unknown status Israel Pancreatic Cancer Infos
NCT02512263 Assessment of Adherence and Efficiency of a Home-based Training Program on Muscular Strength, Endurance and Qol for Colon Cancer Patients Interventional N/A Unknown status Belgium Colon Cancer Infos
NCT02513849 Tamoxifen in Patients With Oesophageal Cancer Interventional Phase 1 Unknown status United Kingdom Cancer Infos
NCT02513849 Tamoxifen in Patients With Oesophageal Cancer Interventional Phase 1 Unknown status United Kingdom Gastrointestinal Neoplasms Infos
NCT02519348 A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma Interventional Phase 2 Active but recruitment closed Italy Hepatocellular Carcinoma Infos
NCT02519348 A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma Interventional Phase 2 Active but recruitment closed Spain Hepatocellular Carcinoma Infos
NCT02519582 Drug Trial to Investigate the Safety and Efficacy of Niclosamide Tablets in Patients With Metastases of a Colorectal Cancer Progressing After Therapy Interventional Phase 2 Recruitment open Germany Colorectal Cancer Infos
NCT02522520 Pedometer Intervention and Health Effects for Sedentary Colorectal Cancer Patients During Adjuvant Chemotherapy Interventional N/A Active but recruitment closed Denmark Colorectal Cancer Infos
NCT02526264 Evaluation of Quality of Life and Period of Hospitalization by Education Interventional N/A Recruitment open Germany Colorectal Cancer Infos
NCT02526836 Complete Mesocolic Excision With Central Vessel Ligation Compared With Conventional Surgery for Colon Cancer Interventional Phase 2/Phase 3 Unknown status Italy Colon Cancer Infos
NCT02528643 A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma Interventional Phase 2 Active but recruitment closed Italy Advanced Hepatocellular Carcinoma Infos
NCT02528643 A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma Interventional Phase 2 Active but recruitment closed Spain Advanced Hepatocellular Carcinoma Infos
NCT02528643 A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma Interventional Phase 2 Active but recruitment closed United Kingdom Advanced Hepatocellular Carcinoma Infos
NCT02530593 QoLiCOL - Quality of Life in Colon Cancer Observational N/A Active but recruitment closed Sweden Colonic Neoplasm Infos
NCT02539537 A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma Interventional Phase 3 Recruitment open France Pancreatic Cancer Infos
NCT02545699 Prospective Trial to Compare ADR of G-EYE™ Colonoscopy With Standard Colonoscopy Interventional N/A Unknown status Israel Colorectal Cancer Infos
NCT02546973 Quality of Life in Patients With Anal Cancer Observational N/A Recruitment open Sweden Anal Cancer Infos
NCT02551458 Comparison of Systematic Surgery Versus Surveillance and Rescue Surgery in Operable Oesophageal Cancer With a Complete Clinical Response to Radiochemotherapy Interventional Phase 2/Phase 3 Recruitment open France Adenocarcinoma of the Oesogastric Junction (Siewert Type I or II) Infos
NCT02551458 Comparison of Systematic Surgery Versus Surveillance and Rescue Surgery in Operable Oesophageal Cancer With a Complete Clinical Response to Radiochemotherapy Interventional Phase 2/Phase 3 Recruitment open France Adenocarcinoma of the Thoracic Oesophagus or Infos
NCT02551458 Comparison of Systematic Surgery Versus Surveillance and Rescue Surgery in Operable Oesophageal Cancer With a Complete Clinical Response to Radiochemotherapy Interventional Phase 2/Phase 3 Recruitment open France Epidermoid Carcinoma or Infos
NCT02551458 Comparison of Systematic Surgery Versus Surveillance and Rescue Surgery in Operable Oesophageal Cancer With a Complete Clinical Response to Radiochemotherapy Interventional Phase 2/Phase 3 Recruitment open France Stage cT2 N1-3 M0 or cT3-T4a N0 or N1-3 M0 Infos
NCT02551991 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma Interventional Phase 1/Phase 2 Active but recruitment closed Spain Pancreatic Cancer Infos
NCT02556281 Prognostic Value of Circulating Tumoral Free DNA Versus Circulating Tumoral Cells in Patients With Colorectal Cancer Stage II-III Interventional N/A Unknown status France Colorectal Neoplasms Infos
NCT02562755 Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone Interventional Phase 3 Active but recruitment closed France Hepatocellular Carcinoma (HCC) Infos
NCT02562755 Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone Interventional Phase 3 Active but recruitment closed Germany Hepatocellular Carcinoma (HCC) Infos
NCT02562755 Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone Interventional Phase 3 Active but recruitment closed Israel Hepatocellular Carcinoma (HCC) Infos
NCT02562755 Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone Interventional Phase 3 Active but recruitment closed Italy Hepatocellular Carcinoma (HCC) Infos
NCT02562755 Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone Interventional Phase 3 Active but recruitment closed Portugal Hepatocellular Carcinoma (HCC) Infos
NCT02562755 Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone Interventional Phase 3 Active but recruitment closed United Kingdom Hepatocellular Carcinoma (HCC) Infos
NCT02564146 First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine Interventional Phase 2 Recruitment open Germany Adenocarcinoma of the Pancreas Infos
NCT02564146 First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine Interventional Phase 2 Recruitment open Germany Metastatic Pancreatic Cancer Infos
NCT02567253 Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer Interventional Phase 2 Recruitment open Belgium Primary Peritoneal Cancer Infos
NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Interventional Phase 2 Recruitment open Belgium Colorectal Cancer Infos
NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Interventional Phase 2 Recruitment open Belgium Pancreatic Cancer Infos
NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Interventional Phase 2 Recruitment open France Colorectal Cancer Infos
NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Interventional Phase 2 Recruitment open France Pancreatic Cancer Infos
NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Interventional Phase 2 Recruitment open Germany Colorectal Cancer Infos
NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Interventional Phase 2 Recruitment open Germany Pancreatic Cancer Infos
NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Interventional Phase 2 Recruitment open Italy Colorectal Cancer Infos
NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Interventional Phase 2 Recruitment open Italy Pancreatic Cancer Infos
NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Interventional Phase 2 Recruitment open Netherlands Colorectal Cancer Infos
NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Interventional Phase 2 Recruitment open Netherlands Pancreatic Cancer Infos
NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Interventional Phase 2 Recruitment open Poland Colorectal Cancer Infos
NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Interventional Phase 2 Recruitment open Poland Pancreatic Cancer Infos
NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Interventional Phase 2 Recruitment open Spain Colorectal Cancer Infos
NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Interventional Phase 2 Recruitment open Spain Pancreatic Cancer Infos
NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Interventional Phase 2 Recruitment open United Kingdom Colorectal Cancer Infos
NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Interventional Phase 2 Recruitment open United Kingdom Pancreatic Cancer Infos
NCT02571036 A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies Interventional Phase 1 Recruitment open Austria Gastrointestinal Stromal Tumors Infos
NCT02571036 A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies Interventional Phase 1 Recruitment open Germany Gastrointestinal Stromal Tumors Infos
NCT02571036 A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies Interventional Phase 1 Recruitment open Italy Gastrointestinal Stromal Tumors Infos
NCT02571036 A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies Interventional Phase 1 Recruitment open Netherlands Gastrointestinal Stromal Tumors Infos
NCT02571036 A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies Interventional Phase 1 Recruitment open Spain Gastrointestinal Stromal Tumors Infos
NCT02571036 A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies Interventional Phase 1 Recruitment open United Kingdom Gastrointestinal Stromal Tumors Infos
NCT02572687 A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies Interventional Phase 1 Active but recruitment closed France Gastric Cancer Infos
NCT02572687 A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies Interventional Phase 1 Active but recruitment closed France Hepatocellular Carcinoma Infos
NCT02572687 A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies Interventional Phase 1 Active but recruitment closed Germany Gastric Cancer Infos
NCT02572687 A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies Interventional Phase 1 Active but recruitment closed Germany Hepatocellular Carcinoma Infos
NCT02572687 A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies Interventional Phase 1 Active but recruitment closed Israel Gastric Cancer Infos
NCT02572687 A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies Interventional Phase 1 Active but recruitment closed Israel Hepatocellular Carcinoma Infos
NCT02572687 A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies Interventional Phase 1 Active but recruitment closed Italy Gastric Cancer Infos
NCT02572687 A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies Interventional Phase 1 Active but recruitment closed Italy Hepatocellular Carcinoma Infos
NCT02572687 A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies Interventional Phase 1 Active but recruitment closed Spain Gastric Cancer Infos
NCT02572687 A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies Interventional Phase 1 Active but recruitment closed Spain Hepatocellular Carcinoma Infos
NCT02574013 Randomized Controlled Trial for Retractor SPONGE Evaluation in Laparoscopic Colorectal Surgery Interventional N/A Recruitment open Netherlands Colorectal Cancer Infos
NCT02575339 MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma Interventional Phase 1/Phase 2 Active but recruitment closed Romania HCC Infos
NCT02575339 MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma Interventional Phase 1/Phase 2 Active but recruitment closed Romania Hepatocellular Carcinoma Infos
NCT02575339 MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma Interventional Phase 1/Phase 2 Active but recruitment closed Romania Liver Cancer Infos
NCT02576431 A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors Interventional Phase 2 Recruitment open Belgium Solid Tumors Harboring NTRK Fusion Infos
NCT02576431 A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors Interventional Phase 2 Recruitment open Czechia Solid Tumors Harboring NTRK Fusion Infos
NCT02576431 A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors Interventional Phase 2 Recruitment open Denmark Solid Tumors Harboring NTRK Fusion Infos
NCT02576431 A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors Interventional Phase 2 Recruitment open France Solid Tumors Harboring NTRK Fusion Infos
NCT02576431 A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors Interventional Phase 2 Recruitment open Germany Solid Tumors Harboring NTRK Fusion Infos
NCT02576431 A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors Interventional Phase 2 Recruitment open Hungary Solid Tumors Harboring NTRK Fusion Infos
NCT02576431 A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors Interventional Phase 2 Recruitment open Ireland Solid Tumors Harboring NTRK Fusion Infos
NCT02576431 A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors Interventional Phase 2 Recruitment open Italy Solid Tumors Harboring NTRK Fusion Infos
NCT02576431 A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors Interventional Phase 2 Recruitment open Poland Solid Tumors Harboring NTRK Fusion Infos
NCT02576431 A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors Interventional Phase 2 Recruitment open Portugal Solid Tumors Harboring NTRK Fusion Infos
NCT02576431 A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors Interventional Phase 2 Recruitment open Russian Federation Solid Tumors Harboring NTRK Fusion Infos
NCT02576431 A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors Interventional Phase 2 Recruitment open Slovakia Solid Tumors Harboring NTRK Fusion Infos
NCT02576431 A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors Interventional Phase 2 Recruitment open Spain Solid Tumors Harboring NTRK Fusion Infos
NCT02576431 A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors Interventional Phase 2 Recruitment open Sweden Solid Tumors Harboring NTRK Fusion Infos
NCT02576431 A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors Interventional Phase 2 Recruitment open United Kingdom Solid Tumors Harboring NTRK Fusion Infos
NCT02576509 An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma Interventional Phase 3 Active but recruitment closed Austria Hepatocellular Carcinoma Infos
NCT02576509 An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma Interventional Phase 3 Active but recruitment closed Belgium Hepatocellular Carcinoma Infos
NCT02576509 An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma Interventional Phase 3 Active but recruitment closed Czechia Hepatocellular Carcinoma Infos
NCT02576509 An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma Interventional Phase 3 Active but recruitment closed France Hepatocellular Carcinoma Infos
NCT02576509 An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma Interventional Phase 3 Active but recruitment closed Germany Hepatocellular Carcinoma Infos
NCT02576509 An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma Interventional Phase 3 Active but recruitment closed Israel Hepatocellular Carcinoma Infos
NCT02576509 An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma Interventional Phase 3 Active but recruitment closed Italy Hepatocellular Carcinoma Infos
NCT02576509 An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma Interventional Phase 3 Active but recruitment closed Poland Hepatocellular Carcinoma Infos
NCT02576509 An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma Interventional Phase 3 Active but recruitment closed Russian Federation Hepatocellular Carcinoma Infos
NCT02576509 An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma Interventional Phase 3 Active but recruitment closed Spain Hepatocellular Carcinoma Infos
NCT02576509 An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma Interventional Phase 3 Active but recruitment closed Sweden Hepatocellular Carcinoma Infos
NCT02576509 An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma Interventional Phase 3 Active but recruitment closed Switzerland Hepatocellular Carcinoma Infos
NCT02576509 An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma Interventional Phase 3 Active but recruitment closed United Kingdom Hepatocellular Carcinoma Infos
NCT02577627 Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOC Observational N/A Unknown status Israel Colon Cancer Infos
NCT02578368 Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction Interventional Phase 3 Recruitment open Germany Gastric Cancer Infos
NCT02591667 Histopathological Response to FOLFOXIRI + Bevacizumab in Peritoneal Metastasis From Colorectal Cancer Interventional Phase 2 Unknown status Austria Colorectal Cancer Infos
NCT02591667 Histopathological Response to FOLFOXIRI + Bevacizumab in Peritoneal Metastasis From Colorectal Cancer Interventional Phase 2 Unknown status Austria Peritoneal Metastasis Infos
NCT02597075 Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative First-line Chemotherapy Interventional N/A Recruitment open Austria Metastatic Colorectal Cancer Infos
NCT02597075 Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative First-line Chemotherapy Interventional N/A Recruitment open Switzerland Metastatic Colorectal Cancer Infos
NCT02597348 Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases Treated by Chemotherapy Interventional Phase 3 Recruitment open France Colorectal Cancer Infos
NCT02606305 Study of Mirvetuximab Soravtansine in Comb. With Bevacizumab, Carboplatin, PLD, Pembrolizumab, or Bevacizumab + Carboplatin in Adults With FRa + Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer Interventional Phase 1/Phase 2 Active but recruitment closed Belgium Primary Peritoneal Cancer Infos
NCT02606305 Study of Mirvetuximab Soravtansine in Comb. With Bevacizumab, Carboplatin, PLD, Pembrolizumab, or Bevacizumab + Carboplatin in Adults With FRa + Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer Interventional Phase 1/Phase 2 Active but recruitment closed Spain Primary Peritoneal Cancer Infos
NCT02614534 Clinical Trial to Evaluate Safety and Efficacy of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) With Mitomycin C Used During Surgery for Treatment of Locally Advanced Colorectal Carcinoma Interventional Phase 3 Recruitment open Spain Colorectal Cancer Infos
NCT02618850 PET/CT Scan as a Tool to Rationalize the Treatment of Patients With Advanced ColoRectal Cancer Undergoing First-line Medical Treatment Interventional N/A Unknown status Italy Colorectal Cancer Stage IV Infos
NCT02619435 Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer Interventional Phase 2 Unknown status Italy Advanced Colorectal Cancer Infos
NCT02624271 Diagnosis of Gastric Precancerous Lesions by a Blood Test GastroPanel in Patients With Increased Gastric Cancer Risk Interventional N/A Unknown status France Gastric Cancer Infos
NCT02624271 Diagnosis of Gastric Precancerous Lesions by a Blood Test GastroPanel in Patients With Increased Gastric Cancer Risk Interventional N/A Unknown status France Gastric Precancerous Lesions Infos
NCT02624726 Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment Interventional Phase 2 Active but recruitment closed Greece Metastatic Colorectal Cancer Infos
NCT02624895 ObservationaL Study on the Qol of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st Line Observational N/A Active but recruitment closed Italy Metastatic Colorectal Cancer Infos
NCT02625610 Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) Interventional Phase 3 Active but recruitment closed France Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction Infos
NCT02625610 Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) Interventional Phase 3 Active but recruitment closed Germany Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction Infos
NCT02625610 Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) Interventional Phase 3 Active but recruitment closed Hungary Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction Infos
NCT02625610 Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) Interventional Phase 3 Active but recruitment closed Italy Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction Infos
NCT02625610 Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) Interventional Phase 3 Active but recruitment closed Romania Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction Infos
NCT02625610 Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) Interventional Phase 3 Active but recruitment closed Russian Federation Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction Infos
NCT02625610 Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) Interventional Phase 3 Active but recruitment closed Spain Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction Infos
NCT02625610 Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) Interventional Phase 3 Active but recruitment closed Turkey Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction Infos
NCT02625610 Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) Interventional Phase 3 Active but recruitment closed United Kingdom Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction Infos
NCT02626377 Multicenter Prospective Cohort of Informal Caregivers in Burgundy and Franche-Comté Interventional N/A Recruitment open France Colorectal Cancer Infos
NCT02628067 Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Interventional Phase 2 Recruitment open Denmark Anal Cancer Infos
NCT02628067 Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Interventional Phase 2 Recruitment open France Anal Cancer Infos
NCT02628067 Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Interventional Phase 2 Recruitment open Germany Anal Cancer Infos
NCT02628067 Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Interventional Phase 2 Recruitment open Israel Anal Cancer Infos
NCT02628067 Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Interventional Phase 2 Recruitment open Italy Anal Cancer Infos
NCT02628067 Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Interventional Phase 2 Recruitment open Netherlands Anal Cancer Infos
NCT02628067 Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Interventional Phase 2 Recruitment open Norway Anal Cancer Infos
NCT02628067 Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Interventional Phase 2 Recruitment open Russian Federation Anal Cancer Infos
NCT02628067 Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Interventional Phase 2 Recruitment open Spain Anal Cancer Infos
NCT02628067 Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Interventional Phase 2 Recruitment open United Kingdom Anal Cancer Infos
NCT02633098 A Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer Interventional Phase 2 Recruitment open United Kingdom Bowel Cancer Infos
NCT02633098 A Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer Interventional Phase 2 Recruitment open United Kingdom Colorectal Cancer Infos
NCT02637687 A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children Interventional Phase 1/Phase 2 Recruitment open Denmark Solid Tumors Harboring NTRK Fusion Infos
NCT02637687 A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children Interventional Phase 1/Phase 2 Recruitment open France Solid Tumors Harboring NTRK Fusion Infos
NCT02637687 A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children Interventional Phase 1/Phase 2 Recruitment open Germany Solid Tumors Harboring NTRK Fusion Infos
NCT02637687 A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children Interventional Phase 1/Phase 2 Recruitment open Ireland Solid Tumors Harboring NTRK Fusion Infos
NCT02637687 A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children Interventional Phase 1/Phase 2 Recruitment open Israel Solid Tumors Harboring NTRK Fusion Infos
NCT02637687 A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children Interventional Phase 1/Phase 2 Recruitment open Italy Solid Tumors Harboring NTRK Fusion Infos
NCT02637687 A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children Interventional Phase 1/Phase 2 Recruitment open Netherlands Solid Tumors Harboring NTRK Fusion Infos
NCT02637687 A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children Interventional Phase 1/Phase 2 Recruitment open Poland Solid Tumors Harboring NTRK Fusion Infos
NCT02637687 A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children Interventional Phase 1/Phase 2 Recruitment open Spain Solid Tumors Harboring NTRK Fusion Infos
NCT02637687 A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children Interventional Phase 1/Phase 2 Recruitment open Sweden Solid Tumors Harboring NTRK Fusion Infos
NCT02637687 A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children Interventional Phase 1/Phase 2 Recruitment open Switzerland Solid Tumors Harboring NTRK Fusion Infos
NCT02637687 A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children Interventional Phase 1/Phase 2 Recruitment open United Kingdom Solid Tumors Harboring NTRK Fusion Infos
NCT02638766 Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST Interventional Phase 2 Recruitment open France Gastrointestinal Stromal Tumors Infos
NCT02638766 Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST Interventional Phase 2 Recruitment open Italy Gastrointestinal Stromal Tumors Infos
NCT02638766 Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST Interventional Phase 2 Recruitment open Spain Gastrointestinal Stromal Tumors Infos
NCT02646462 Systematic Lymph Node Sampling and Analysis in Patients With Pancreatic Cancer Observational N/A Unknown status Denmark Pancreatic Cancer Infos
NCT02647099 Adjuvant Low Dose Aspirin in Colorectal Cancer Interventional Phase 3 Recruitment open Sweden Colorectal Cancer Infos
NCT02665312 Cardiotoxicity and Risk Factors in Patients With Colorectal Cancer Receiving Fluoropyrimidine Observational N/A Unknown status Italy Colorectal Cancer Infos
NCT02668913 LCC-CARIS-01: Molecular Profiling in Gynaecological Cancer Interventional Phase 1/Phase 2 Unknown status United Kingdom Peritoneal Cancer Infos
NCT02672774 Novel Endoscopic Imaging Methods for the Evaluation of Blood Vessels in Gastrointestinal Cancers Interventional N/A Unknown status Romania Colorectal Cancer Infos
NCT02672774 Novel Endoscopic Imaging Methods for the Evaluation of Blood Vessels in Gastrointestinal Cancers Interventional N/A Unknown status Romania Gastric Cancer Infos
NCT02672774 Novel Endoscopic Imaging Methods for the Evaluation of Blood Vessels in Gastrointestinal Cancers Interventional N/A Unknown status Romania Gastrointestinal Neoplasms Infos
NCT02674100 American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry Observational N/A Recruitment open United Kingdom Pancreatic Cancer Infos
NCT02674373 Prognostic and Predictive Impact of Circulating Tumor DNA in Gastric Cancer Treatment Observational N/A Unknown status France Gastric Cancer Infos
NCT02678182 Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial Interventional Phase 2 Recruitment open United Kingdom Adenocarcinoma of the Gastro-oesophageal Junction Infos
NCT02678182 Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial Interventional Phase 2 Recruitment open United Kingdom Adenocarcinoma of the Oesophagus Infos
NCT02678182 Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial Interventional Phase 2 Recruitment open United Kingdom Adenocarcinoma of the Stomach Infos
NCT02687321 The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer Observational N/A Unknown status Czechia Ovarian Neoplasms Infos
NCT02687321 The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer Observational N/A Unknown status Hungary Ovarian Neoplasms Infos
NCT02687321 The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer Observational N/A Unknown status Poland Ovarian Neoplasms Infos
NCT02687321 The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer Observational N/A Unknown status Slovakia Ovarian Neoplasms Infos
NCT02687321 The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer Observational N/A Unknown status Spain Ovarian Neoplasms Infos
NCT02687321 The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer Observational N/A Unknown status Ukraine Ovarian Neoplasms Infos
NCT02693847 Natural History of Liver Cirrhosis Diagnosed by Transient Elastography in HIV/HCV-coinfected Patients Observational N/A Recruitment open Spain Hepatocellular Carcinoma Infos
NCT02697084 Individual Following in Anal Cancer With PET/CT Observational N/A Recruitment open France Anal Cancer Infos
NCT02701088 Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life Interventional Phase 2 Recruitment open France Locally Advanced Anal Canal Cancer Infos
NCT02702401 Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) Interventional Phase 3 Active but recruitment closed Belgium Hepatocellular Carcinoma Infos
NCT02702401 Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) Interventional Phase 3 Active but recruitment closed Denmark Hepatocellular Carcinoma Infos
NCT02702401 Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) Interventional Phase 3 Active but recruitment closed France Hepatocellular Carcinoma Infos
NCT02702401 Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) Interventional Phase 3 Active but recruitment closed Germany Hepatocellular Carcinoma Infos
NCT02702401 Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) Interventional Phase 3 Active but recruitment closed Hungary Hepatocellular Carcinoma Infos
NCT02702401 Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) Interventional Phase 3 Active but recruitment closed Ireland Hepatocellular Carcinoma Infos
NCT02702401 Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) Interventional Phase 3 Active but recruitment closed Israel Hepatocellular Carcinoma Infos
NCT02702401 Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) Interventional Phase 3 Active but recruitment closed Italy Hepatocellular Carcinoma Infos
NCT02702401 Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) Interventional Phase 3 Active but recruitment closed Norway Hepatocellular Carcinoma Infos
NCT02702401 Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) Interventional Phase 3 Active but recruitment closed Poland Hepatocellular Carcinoma Infos
NCT02702401 Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) Interventional Phase 3 Active but recruitment closed Russian Federation Hepatocellular Carcinoma Infos
NCT02702401 Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) Interventional Phase 3 Active but recruitment closed Turkey Hepatocellular Carcinoma Infos
NCT02702401 Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) Interventional Phase 3 Active but recruitment closed United Kingdom Hepatocellular Carcinoma Infos
NCT02702414 Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) Interventional Phase 2 Active but recruitment closed Belgium Hepatocellular Carcinoma Infos
NCT02702414 Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) Interventional Phase 2 Active but recruitment closed France Hepatocellular Carcinoma Infos
NCT02702414 Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) Interventional Phase 2 Active but recruitment closed Germany Hepatocellular Carcinoma Infos
NCT02702414 Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) Interventional Phase 2 Active but recruitment closed Italy Hepatocellular Carcinoma Infos
NCT02702414 Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) Interventional Phase 2 Active but recruitment closed Sweden Hepatocellular Carcinoma Infos
NCT02702414 Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) Interventional Phase 2 Active but recruitment closed United Kingdom Hepatocellular Carcinoma Infos
NCT02702986 Safety and Feasibility of imILT Locally Advanced Pancreatic Cancer (LAPC) Interventional Phase 1 Active but recruitment closed Italy Pancreatic Cancer Infos
NCT02704832 Role of Geriatric Intervention in Treatment of Older Patients With Cancer (PREPARE) Interventional Phase 3 Recruitment open France Colorectal Cancer Infos
NCT02705300 Side Effects to FOLFOXIRI + Tocotrienol/Placebo as First Line Treatment of Metastatic Colorectal Cancer Interventional Phase 2 Active but recruitment closed Denmark Colorectal Cancer Infos
NCT02707159 Circulating Tumor Cells as Tools for Therapy Response in Nab-paclitaxel Treated Metastatic Pancreatic Cancer Patients Interventional Phase 2 Unknown status Norway Metastatic Pancreatic Cancer Infos
NCT02707796 Correlation Between Partial Oxygen Pressure and Oxygen Reserve Index Interventional N/A Unknown status Turkey COLON CANCER Infos
NCT02715141 Molecular Stool Testing for Colorectal Cancer Surveillance Observational N/A Unknown status Netherlands Colorectal Cancer Infos
NCT02715882 Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer Interventional Phase 2 Unknown status Russian Federation Colorectal Cancer Infos
NCT02716012 First-in-Human Safety and Tolerability Study of MTL-CEBPA in Patients With Advanced Liver Cancer Interventional Phase 1 Recruitment open United Kingdom Hepatocellular Carcinoma Infos
NCT02716012 First-in-Human Safety and Tolerability Study of MTL-CEBPA in Patients With Advanced Liver Cancer Interventional Phase 1 Recruitment open United Kingdom Liver Cancer Infos
NCT02721056 NBTXR3 Crystalline Nanoparticles and Stereotactic Body Radiation Therapy in the Treatment of Liver Cancers Interventional Phase 1/Phase 2 Unknown status France Hepatocellular Carcinoma Infos
NCT02721056 NBTXR3 Crystalline Nanoparticles and Stereotactic Body Radiation Therapy in the Treatment of Liver Cancers Interventional Phase 1/Phase 2 Unknown status France Liver Cancer Infos
NCT02726243 Intestinal Microbiota and Colorectal Cancer in Inflammatory Bowel Disease Observational N/A Unknown status France